In-depth briefings on agency actions, clinical and preclinical research, and state and federal law and policy — with primary sources, scores, and clear limits on claims.
A 2026 cost-effectiveness analysis compares ketamine and ECT for nonpsychotic treatment-resistant depression, weighing costs and QALYs. The findings may influence clinical guidelines, reimbursement, and patient access in the US.
Oct 22, 2026
PolicyCBP's extension of the de minimis exemption suspension delays stricter controls on small-value mail imports, affecting psychedelic research and unregulated substance sourcing. Stakeholders should prepare for future enforcement and evolving compliance requirements.
Oct 22, 2026
Clinical TrialsA new meta-analysis published in October 2026 confirms moderate, rapid-acting efficacy of low-dose ketamine for treatment-resistant depression. The findings support cautious clinical use, highlight monitoring needs, and may influence future guidelines and regulatory decisions.
Oct 21, 2026
Clinical TrialsA new study finds that willingness to join psychedelic clinical trials is shaped by participants' expectations and personality traits, highlighting a selection bias that may skew efficacy estimates and limit generalizability.
Oct 21, 2026
Clinical TrialsA new phase 2 trial finds psilocybin reduces inflammation in Parkinson’s disease, suggesting a possible disease-modifying role. This insight could shift research and regulatory focus toward psychedelics’ neuroprotective potential, but key risks and unknowns remain.
Oct 21, 2026
Clinical TrialsA recent secondary analysis of a randomized trial shows MDMA-assisted therapy enhances wellbeing and interconnectedness in social anxiety disorder, even without reducing core symptoms. This finding may reshape outcome measures and trial design in psychedelic research.
Oct 20, 2026
NeuroscienceA 2026 narrative review synthesizes omics data on TMS in treatment-resistant depression (TRD), highlighting molecular and circuit-level mechanisms. The findings inform biomarker and mechanistic strategies increasingly adopted in psychedelic research.
Oct 20, 2026
Clinical TrialsA new secondary analysis of a U.S. MDMA-assisted therapy trial for social anxiety disorder reveals that session experiences of interconnectedness and self-transcendence predict post-treatment wellbeing, but not symptom reduction. This finding could reshape outcome measures in future psychedelic research and regulatory review.
Oct 20, 2026
NeuroscienceA robust deep learning model now enables more accurate, scalable sleep stage classification in preclinical studies, even under varied pharmacological interventions—advancing psychedelic and CNS drug research reliability.
Oct 20, 2026
Clinical TrialsOptimi Health has finalized GMP-grade MDMA manufacturing for a Phase 3 PTSD trial, addressing key supply and regulatory hurdles. This development signals maturing industry capacity and highlights both opportunities and unresolved risks in psychedelic-assisted therapy research.
Oct 20, 2026
Clinical TrialsOptimi Health has finalized MDMA production for Phase 3 PTSD trials in Canada and Israel, and for commercial supply in Australia, advancing international clinical research and highlighting progress in psychedelic medicine supply chains.
Oct 20, 2026
MarketPharmaceutical firms are expediting ketamine drug development in the U.S., driven by clinical evidence and shifting regulations. This trend may expand treatment options, but raises concerns about pricing, intellectual property, and equitable access.
Oct 20, 2026
EthicsA new systematic review highlights fragmented progress and ongoing exclusion of ethnic minorities in health and governance systems. For psychedelic research, the findings call for structural change, intercultural justice, and genuine inclusion of Indigenous and Afro-descendant communities.
Oct 19, 2026
EthicsThis briefing examines how Michael Pollan’s works have shaped Western narratives on psilocybin, raising unresolved ethical, cultural, and policy issues regarding Mazatec Indigenous rights and benefit-sharing as the psychedelic industry expands.
Oct 19, 2026
NeuroscienceA 2026 study using advanced brain modeling finds that anhedonia is marked by diminished ascending subcortical drive and a shift in cortico-subcortical hierarchy, informing future clinical trial design and biomarker development for mood and psychotic disorders.
Oct 19, 2026
NeuroscienceA 2026 study maps how chronic stress remodels the lateral habenula (LHb) in mice, identifying a window where ketamine reverses neuronal changes linked to depression. These findings inform timing and targets for rapid-acting antidepressant interventions.
Oct 19, 2026
Clinical TrialsA 2026 Irish cohort study reports that hexahydrocannabinol (HHC)-associated psychosis presents with more affective symptoms and formal thought disorder than cannabis-related cases. These findings highlight the need for updated screening and clinical protocols as novel cannabinoids enter psychiatric practice.
Oct 19, 2026
NeuroscienceA 2026 mouse study finds that calcium-permeable AMPA receptors in the dorsomedial striatum play a causal role in aversion-resistant alcohol drinking, advancing understanding of addiction mechanisms and informing future translational research.
Oct 19, 2026
Clinical TrialsMedia coverage of MDMA for PTSD shapes perceptions, but the clinical and regulatory landscape remains complex. We analyze trial evidence, FDA review status, safety debates, and the implications for policy, research, and the emerging psychedelic sector.
Oct 19, 2026
Clinical TrialsA recent narrative review synthesizes clinical evidence that intravenous ketamine induces rapid but short-lived symptom relief in obsessive-compulsive disorder (OCD), underscoring its experimental status and the need for further research on safety and maintenance protocols.
Oct 19, 2026
PolicyA 2026 review highlights that safety and efficacy claims for Cannabis and Psilocybe must be product-specific, not generalized. It proposes a claim-linked extrapolation record to improve regulatory, clinical, and commercial transparency as these markets diversify.
Oct 19, 2026
Clinical TrialsEsketamine (FDA-approved) and generic ketamine (off-label) differ in clinical use, insurance coverage, and regulatory oversight for depression. This analysis clarifies key distinctions, risks, and evolving standards shaping psychiatric care and access in the U.S.
Oct 19, 2026
PolicyThe University of Mississippi's NCNPR has applied for DEA registration to manufacture controlled substances in bulk, signaling a shift in domestic supply for psychedelic research and clinical trials. This move could streamline access, reduce import reliance, and accelerate scientific progress.
Oct 19, 2026
NeuroscienceA 2026 review argues for a phenomenological taxonomy of altered states in psychedelic and hypnosis research, introducing the Context–State–Stance–Trait model and 'Fundamental Peace' as testable constructs. This approach may clarify mechanisms and improve experimental controls in psychedelic clinical trials.
Oct 18, 2026
Clinical TrialsA new clinical trial shows psilocybin’s initial antidepressant benefits diminish over a year, equaling placebo at 12 months. This finding raises key questions for researchers, clinicians, and policymakers about the durability and design of psychedelic-assisted depression treatments.
Oct 18, 2026
LegalThe DEA and Iowa officials have authorized a psychedelic church to legally import and manufacture ayahuasca, establishing a new legal pathway for religious entheogen use in the US and shaping future policy for non-medical psychedelic access.
Oct 17, 2026
Public HealthA 2026 study finds meditation is most commonly combined with alcohol and cannabis, not classic psychedelics. No clear well-being benefits emerge from combining psychedelics or cannabis with meditation, but meditation may mitigate some harms from alcohol or other drug use.
Oct 17, 2026
Clinical TrialsA 2026 analysis directly compares ketamine and psilocybin for treatment-resistant depression, revealing key differences in onset, remission durability, and cost-effectiveness. The findings may inform clinical choices, payer coverage, and trial designs.
Oct 17, 2026
Clinical TrialsPsychedelic clinical trial participants are voicing concerns about protocol limitations, integration support, and outcome measures, prompting researchers and regulators to reconsider patient-centered approaches in future studies.
Oct 17, 2026
Public HealthA new paper examines why public doubt about antidepressants endures despite scientific consensus, exploring the impact of critical psychiatry and 'manufactured doubt.' The findings offer important context for psychedelic science and policy.
Oct 16, 2026
Clinical TrialsA 2023–2025 multicenter retrospective study in Brazil found that both intravenous and subcutaneous esketamine protocols achieved similar outcomes for treatment-resistant depression, with subcutaneous delivery offering fewer dissociative side effects and simpler logistics.
Oct 16, 2026
Public HealthA recent undercover investigation highlights inconsistent therapy practices at Oregon’s psilocybin centers. The findings may shape public trust, regulatory action, and the standards for psychedelic-assisted care across the U.S.
Oct 16, 2026
NeuroscienceA 2026 rat study links esketamine’s alleviation of pain and depression symptoms to Wnt4 signaling changes in the anterior cingulate cortex, offering new molecular clues but no immediate clinical translation.
Oct 16, 2026
NeuroscienceA 2026 study demonstrates ketamine’s ability to remodel synaptic and monoaminergic pathways in human iPSC-derived neurons, providing direct mechanistic insight relevant for drug development and personalized psychiatry approaches.
Oct 16, 2026
Clinical TrialsA new US survey reveals ibogaine and 5-MeO-DMT have the highest rates of self-reported adverse outcomes among psychedelics, while psilocybin, LSD, and MDMA account for the most total reports due to wider use. The findings inform clinical and regulatory risk assessments.
Oct 16, 2026
PolicyBelgium may soon permit psychedelic therapy for patients with hard-to-treat depression outside of clinical trials, signaling a significant policy shift in the EU. This move could influence European regulatory frameworks, accelerate real-world evidence gathering, and reshape access to novel mental health treatments.
Oct 16, 2026
Clinical TrialsA 2026 study shows ketamine-assisted psychotherapy causes lasting DNA methylation changes in major depressive disorder patients, providing a biological mechanism for its effects and guiding future clinical and regulatory strategies.
Oct 15, 2026
Clinical TrialsA 2026 meta-research study shows major gaps in MeSH indexing for depression biomarker studies, with most records lacking information on sampling site. This undermines systematic reviews and regulatory assessment, especially for psychedelic trials using biomarker endpoints.
Oct 15, 2026
Public HealthA new review details the mechanisms, clinical presentation, and management of ketamine-induced cystitis, emphasizing early detection, multidisciplinary care, and research gaps as ketamine's therapeutic and recreational use expands.
Oct 15, 2026
Clinical TrialsA 2026 longitudinal study reports peripheral DNA methylation changes in adults with major depressive disorder after ketamine-assisted psychotherapy, hinting at molecular mechanisms and future biomarker potential, but clinical translation remains premature.
Oct 15, 2026
Clinical TrialsA 2026 study identifies baseline emotional response criterion and changes in emotional bias as potential markers for predicting and tracking esketamine response in treatment-resistant depression, offering new avenues for personalized care if findings are validated.
Oct 15, 2026
Clinical TrialsA 2026 article highlights why clearly defining 'psychotherapy' and 'psychological support' in psychedelic trials is crucial for regulatory approval, reproducibility, and cross-study comparisons, with implications for policy and research.
Oct 15, 2026
Public HealthA major 2026 review synthesizes global depression data, mechanisms, and treatment gaps, emphasizing the need for innovative approaches such as ketamine/esketamine and digital therapeutics. The analysis explores efficacy, risks, and policy implications for multidisciplinary strategies.
Oct 15, 2026
LegalPolice raids on Colorado Springs businesses for alleged illicit psilocybin and THC sales illustrate the ongoing legal uncertainty and enforcement risks facing operators, researchers, and patients amid evolving state and local regulations.
Oct 15, 2026
EthicsA 2026 ethics analysis of psilocybin-assisted therapy in advanced cancer care highlights meaningful consent despite unpredictable experiences, calls for broader outcome measures, and outlines practical challenges for clinicians and policymakers.
Oct 15, 2026
PolicyThe EPA's October 2026 SNURs under TSCA introduce mandatory pre-notification and review for manufacturing or processing designated chemicals, affecting psychedelic research and industry by increasing compliance complexity and potential delays.
Oct 15, 2026
Clinical TrialsA recent narrative review examines psilocybin’s potential in treating depression, pain, and inflammation, focusing on mechanisms and the intersection of mental and physical health. The synthesis highlights research gaps and future clinical trial needs.
Oct 14, 2026
LegalActive police raids on suspected illegal psilocybin and THC sales in Colorado Springs reveal ongoing enforcement risks for unregulated operators, emphasizing the distinction between regulated, decriminalized, and illicit markets amid evolving state laws.
Oct 14, 2026
Clinical TrialsA 2026 Brazilian review finds ketamine and esketamine offer rapid, short-term relief for severe depression and suicidality, but effects are inconsistent with repeated use. Safety concerns and unclear long-term benefit limit their role to adjunctive, not replacement, care.
Oct 14, 2026
Clinical TrialsA 2026 PubMed review on ibogaine for substance use disorders summarizes preclinical and clinical findings, outlines neurobiological mechanisms, and discusses research and policy implications. Despite promise, regulatory and safety hurdles remain substantial.
Oct 14, 2026
Clinical TrialsA recent observational case report (n=14) found group psilocybin retreats significantly increased social connectedness and reduced distress, highlighting the need for further controlled studies on collective psychedelic therapy models.
Oct 14, 2026
PolicyA review of Ecuador’s legal framework for ayahuasca and ancestral medicine in Pastaza reveals significant regulatory gaps in safety, dosage, and Indigenous knowledge protection, highlighting the need for intercultural, community-driven policy.
Oct 14, 2026
Public HealthA 2026 survey documents consumer-reported health risks of unsupervised ayahuasca use, including severe nausea, hypertension, and psychological aftereffects. The findings highlight the urgent need for harm reduction, medical screening, and regulatory frameworks as ayahuasca use grows outside indigenous settings.
Oct 14, 2026
Clinical TrialsIbogaine is under review as a potential treatment for substance use disorders, offering unique neurobiological effects but posing significant safety and regulatory challenges. This analysis examines its mechanisms, evidence, risks, and future clinical and policy directions.
Oct 14, 2026
NeuroscienceA 2026 study provides the first human evidence that blood-brain barrier (BBB) permeability is linked to disrupted brain network architecture and symptom severity in treatment-resistant depression, informing future psychedelic research.
Oct 14, 2026
Clinical TrialsA recent case report documents significant increases in social connectedness and reduced distress among participants in a group psilocybin retreat, highlighting the need for further research into group-based psychedelic models and their implications for clinical practice and policy.
Oct 14, 2026
NeuroscienceA 2026 theoretical paper proposes a unified model of reality construction via active inference, connecting brain prediction, social consensus, and psychopathology. This framework holds significant implications for understanding altered states and designing future psychedelic research.
Oct 14, 2026
Clinical TrialsA recent case report documents increased social connectedness and reduced distress among participants in a group psilocybin retreat, suggesting group-based interventions may offer unique benefits and informing future research and policy.
Oct 14, 2026
Clinical TrialsA 2026 qualitative study highlights participant-driven recommendations to improve support, communication, and integration in psychedelic clinical trials, with implications for trial design, ethics, and future policy as psychedelic therapies advance.
Oct 14, 2026
Clinical TrialsA recent randomized controlled trial shows that adjunctive esketamine at 0.25 mg/kg can reduce opioid consumption and improve pain control after lumbar decompression surgery, suggesting a new approach for multimodal analgesia protocols.
Oct 14, 2026
Clinical TrialsA 2026 paper highlights the absence of standardized aftercare and integration protocols in psilocybin therapy, especially in Oregon and Colorado. This gap may affect patient outcomes and the legitimacy of new service models, prompting calls for robust, evidence-based follow-up frameworks.
Oct 14, 2026
Clinical TrialsAn October 2026 study demonstrates that AI-driven, protocol-based queries of ClinicalTrials.gov can rapidly map the global psychedelic clinical trial landscape, highlighting compound focus, trial design, and geographic disparities.
Oct 14, 2026
PolicyThe DEA will continue to classify MGM-15 and MGM-16 as Schedule I substances, maintaining strict federal controls and limiting research and commercial opportunities for these kratom analogs.
Oct 14, 2026
PolicyThe DEA’s temporary Schedule I placement of 7-hydroxymitragynine and mitragynine pseudoindoxyl above a specified threshold imposes new research and manufacturing barriers, with significant implications for kratom science, industry, and patient access.
Oct 14, 2026
Clinical TrialsA new review synthesizes evidence on antidepressants’ effects on cognition in major depressive disorder (MDD), noting limited but promising data for ketamine and psychedelics. The article calls for large, standardized trials with cognition as a primary endpoint to inform precision medicine.
Oct 13, 2026
NeuroscienceA systematic review of preclinical zebrafish studies finds esketamine alters neurodevelopment and behavior in a dose- and exposure-dependent manner, highlighting both acute benefits and potential long-term neurotoxicity risks relevant to clinical translation.
Oct 13, 2026
Clinical TrialsA major 2026 systematic review finds that both neuroplastic changes and acute psychedelic experiences, alongside psychotherapy, contribute to outcomes in psychedelic-assisted therapy. However, the necessity of the subjective experience for lasting benefit remains unproven, shaping future research and policy.
Oct 13, 2026
NeuroscienceA 2026 study using large-scale calcium imaging in awake mice shows arousal-linked cortical networks operate near criticality, optimizing information processing. These findings may inform how psychedelics alter perception by modulating brain network dynamics.
Oct 13, 2026
Clinical TrialsA new rat study shows psilocybin and norbaeocystin can trigger acute, reversible anxiety-like behaviors, with effects varying by sex and dose. These findings inform risk assessment and trial design as psychedelics progress toward clinical use.
Oct 13, 2026
PolicyAI tools offer promise for improving FDA surveillance of neuropsychiatric drug safety, but significant challenges remain in bias, validation, and regulatory oversight. This analysis reviews current systems, new AI approaches, and future directions for psychedelic and related therapies.
Oct 13, 2026
Clinical TrialsA 2026 review synthesizes clinical and molecular evidence supporting intranasal esketamine as a rapid, effective intervention for treatment-resistant depression and acute suicidality, highlighting both benefits and monitoring needs.
Oct 13, 2026
NeuroscienceA new preclinical study shows rTMS elicits different behavioral and molecular responses in rats with treatment-resistant vs. treatment-responsive depression, underscoring the need for personalized neuromodulation approaches.
Oct 13, 2026
Clinical TrialsA systematic review of nearly 2,000 participants suggests psychedelics may reduce neuroticism and influence personality traits, but small sample sizes and methodological limits highlight the need for larger, controlled studies to clarify long-term effects and mechanisms.
Oct 13, 2026
Clinical TrialsEarly findings indicate that ketamine’s efficacy in treatment-resistant depression (TRD) varies by depressive subtype and trauma history. The study urges further research into personalized protocols and integration with psychotherapy.
Oct 13, 2026
NeuroscienceA 2026 UK study shows PET, DWI, and EEG can reliably track synaptic plasticity in humans after DMT and ketamine, validating these as surrogate endpoints for future psychedelic trials despite no significant post-drug changes.
Oct 13, 2026
Public HealthPharmacists across the U.S. are preparing for the integration of psychedelic medicines, with new training programs emerging to address safety, education, and regulatory compliance ahead of possible FDA approvals.
Oct 13, 2026
PolicyVicente LLP's October 2026 webinar reflects increasing attention to the regulatory, operational, and investment landscape for psychedelic medicine following FDA approval, with key implications for clinics and investors.
Oct 13, 2026
PolicyOregon’s inaugural independent safety audit of licensed psilocybin centers validates the state’s regulatory framework, but high costs limit access. This outcome informs other jurisdictions considering similar psychedelic policies and highlights ongoing equity challenges.
Oct 13, 2026
Public HealthA 2026 Washington University study reports that psilocybin providers are following safety guidelines, bolstering the legitimacy of regulated psychedelic services and informing future policy. This analysis examines the study's context, implications, and remaining uncertainties.
Oct 12, 2026
CommunityA 2026 study explores peyote’s role in Ho-Chunk healing and the Native American Church, highlighting indigenous trauma recovery models and raising critical questions for psychedelic policy, religious freedom, and cultural preservation.
Oct 12, 2026
NeuroscienceA 2026 preclinical trial reports that acute unilateral DBS of the basolateral amygdala in rats does not affect locomotion, anxiety, or fear memory. These findings clarify safety and tolerability for neuromodulation in psychiatric research.
Oct 12, 2026
Clinical TrialsA case report describes sustained remission of mutism in DNSD following oral ketamine-assisted psychotherapy, highlighting a potential new indication and underlining the need for controlled studies to assess efficacy, safety, and therapeutic mechanisms.
Oct 12, 2026
Clinical TrialsA recent Ukrainian review details the history and current evidence for psychedelic-assisted therapy, highlighting promising findings but emphasizing the need for robust, large-scale studies before broader clinical adoption.
Oct 12, 2026
Clinical TrialsA 2026 review introduces a standardized diagnostic approach for visual snow syndrome (VSS), a condition sometimes reported after psychedelic use. This protocol may improve adverse event tracking and inform future research on neurological risks and mechanisms.
Oct 12, 2026
NeuroscienceA preclinical study finds that Nav1.7 channel loss in sensory neurons enhances suzetrigine analgesia via endogenous opioid pathways, suggesting new strategies for pain management and intersecting with broader research on opioid and psychedelic mechanisms.
Oct 12, 2026
Clinical TrialsA new randomized controlled trial from China shows that low-dose intravenous esketamine improves pain and sedation during emergency C-sections after failed epidural, without negative impacts on maternal hemodynamics or early neonatal outcomes.
Oct 12, 2026
Clinical TrialsA 2026 NCBI meta-analysis synthesizes evidence on intravenous ketamine augmentation in treatment-resistant depression, informing clinical, regulatory, and payer strategies with updated efficacy and safety data.
Oct 12, 2026
PolicyOregon’s legal psilocybin centers prioritize safety but face criticism over high session costs, limiting access. This briefing analyzes the operational model, equity concerns, and implications for jurisdictions considering regulated psychedelic services.
Oct 12, 2026
Clinical TrialsA 2026 RCT in healthcare workers with COVID-related depression found that mystical experiences mediate the positive effects of psilocybin-assisted group therapy combined with Mindfulness-Based Stress Reduction on mindfulness and depressive symptoms, but larger studies are needed.
Oct 11, 2026
Clinical TrialsAI-driven generative and predictive models are streamlining preclinical drug discovery, design, and safety assessment, offering new opportunities and challenges for psychedelic research and industry stakeholders.
Oct 11, 2026
NeuroscienceA new systematic review reveals that total BDNF is unreliable as a standalone biomarker for PTSD. Integrating genetic, epigenetic, and protein measures may improve prognosis and guide personalized interventions, including psychedelic trials.
Oct 11, 2026
Clinical TrialsA living systematic review and open-data meta-analysis now compiles all randomized trials of MDMA-assisted therapy for PTSD, showing moderate efficacy but emphasizing persistent risks, bias, and evidence limitations. This resource aims to inform researchers, clinicians, and policymakers as the field evolves.
Oct 11, 2026
LegalA high-profile op-ed warns of mounting legal liability for ketamine clinics and prescribers. This signals growing scrutiny of clinical standards, insurance coverage, and ethical responsibilities, potentially impacting access and future regulation.
Oct 11, 2026
Clinical TrialsA new systematic review highlights that classic psychedelics acutely alter REM sleep and sleep architecture in both preclinical and human studies. Findings reveal transient, heterogeneous effects and underscore the need for better-controlled research to inform clinical practice and safety.
Oct 10, 2026
Public HealthA randomized clinical trial in US pediatric clinics shows that an online, culturally tailored family intervention reduces initiation of drugs—including psychedelics—among Hispanic adolescents. The study informs prevention strategies and future public health policy.
Oct 09, 2026
Public HealthA Swedish thesis finds cannabis use and cannabis use disorder are significantly underreported, especially among young adults. The findings raise urgent questions for drug policy reform, healthcare capacity, and research methodology.
Oct 09, 2026
NeuroscienceRecent preclinical research shows nicotine amplifies fentanyl-driven dopamine release in the dorsal lateral striatum, elucidating a neurobiological mechanism that may heighten opioid use disorder risk among polysubstance users. This finding informs future addiction research and interventions.
Oct 09, 2026
Clinical TrialsA systematic review finds no direct trials of psychedelics in neurosurgical patients, but highlights esketamine and psilocybin as promising candidates. Translational barriers and safety concerns remain significant.
Oct 09, 2026
NeuroscienceA new study identifies IL-6 trans-signaling and sgp130 insufficiency as key mechanisms in treatment-resistant depression (TRD), suggesting a path for precision immunopsychiatry and informing future clinical trial design.
Oct 09, 2026
NeuroscienceGermany's DZPG Model Systems infrastructure unites advanced animal, cellular, and human models with high-throughput analytics, aiming to revolutionize mechanistic mental health research and support the development of novel interventions, including psychedelics.
Oct 09, 2026
Clinical TrialsA new systematic review synthesizes current evidence on ketamine and esketamine exposure in breastfeeding mothers, evaluating pharmacokinetics and infant safety outcomes. The review identifies significant data gaps, informing future research and risk assessment.
Oct 09, 2026
MarketTechBio 3.0 integrates AI, generative chemistry, and automated experimentation into a closed-loop system for drug discovery. This approach could accelerate psychedelic compound development, but faces significant technical and translational challenges.
Oct 09, 2026
Clinical TrialsThe credibility of psychedelic clinical trials depends on robust blinding, ethical safeguards, and safety protocols. Ongoing debates influence IRB standards, trial reproducibility, and the pace of clinical translation, with unique challenges and emerging solutions.
Oct 09, 2026
CommunityA Yaqui-led clinic in Sonora, Mexico, integrates ayahuasca within a culturally grounded mental health program, showing feasibility and community benefits but facing legal and resource challenges. This model underscores the importance of Indigenous authority in psychedelic care.
Oct 09, 2026
PolicyThe FDA’s willingness to enable ibogaine clinical trials in the US signals a new era for psychedelic research, potentially accelerating addiction treatment studies and reshaping regulatory pathways for novel compounds.
Oct 09, 2026
EthicsA 2026 German study finds that patient safety in (es)ketamine therapy depends on clinician behavior, therapeutic presence, and post-acute support, highlighting ethical demands for flexible, patient-centered care beyond standard protocols.
Oct 08, 2026
NeuroscienceRecent research demonstrates that key molecular pathways involved in antidepressant action exhibit diurnal fluctuations in mouse brain regions, suggesting circadian timing may affect efficacy and interpretation of both psychedelic and standard antidepressant trials.
Oct 08, 2026
Public HealthA major 2026 survey of over 1,000 psychedelic users reveals that adverse reactions in naturalistic settings correlate with current psychopathology and lower well-being, underscoring the need for nuanced harm reduction and further prospective research.
Oct 08, 2026
Clinical TrialsA new AI model accurately predicts 30-day suicide risk in bipolar depression, breaking prior performance ceilings. This advance could shape safety screening and access protocols in psychedelic research, especially for high-risk populations.
Oct 08, 2026
Public HealthChiral drugs, including synthetic psychoactives, persist in aquatic environments and biological samples. Their stereoselective effects complicate forensic analysis and pose emerging risks for public health and environmental policy.
Oct 08, 2026
Clinical TrialsA new study introduces interoceptive training as a preparatory component in psilocybin therapy for cancer patients, aiming to improve therapeutic outcomes by addressing the somatic dimensions of anxiety and depression. This approach may reshape clinical protocols and standards.
Oct 08, 2026
Clinical TrialsA new analysis reveals that music playlists used in psilocybin therapy lack consistent structure across pharmacodynamic phases, raising concerns about protocol reproducibility and the need for evidence-based music curation in psychedelic-assisted treatment.
Oct 08, 2026
Clinical TrialsA new randomized controlled trial shows high-dose LSD increases working memory-related brain activity in patients with major depressive disorder, but these neural effects are not linked to mood changes. This dissociation informs future psychedelic research and clinical trial design.
Oct 08, 2026
Clinical TrialsA pioneering RCT investigates the safety of circular breathwork in adults with subclinical depression and trauma histories, providing much-needed adverse event data to guide its use in psychotherapy and adjacent mental health fields.
Oct 08, 2026
NeuroscienceA major 2026 study offers the first formal mapping of how five psychedelics reorganize information processing in the human cortex, resolving prior contradictions and informing clinical research, trial design, and policy.
Oct 08, 2026
Clinical TrialsA planned U.S. clinical trial will evaluate a psychedelic for methamphetamine use disorder in people with HIV, targeting a critical unmet need. The study's design and population may influence future FDA submissions and public health policy.
Oct 08, 2026
Clinical TrialsFilament Health's agreement to supply PEX010 psilocybin for US research highlights progress in regulated psychedelic trials, supporting FDA standards and industry readiness for future commercialization.
Oct 08, 2026
PolicyThe FDA’s engagement with ibogaine trial design, Compass Pathways’ pricing discussions, and new psychedelic brand names signal regulatory and commercial momentum, but uncertainties in safety, access, and market dynamics remain.
Oct 08, 2026
Clinical TrialsA 2026 qualitative study examines acute inhaled DMT experiences in Brazilian clinical settings, highlighting the influence of cultural, regulatory, and contextual factors on patient outcomes and safety.
Oct 07, 2026
NeuroscienceA 2026 peer-reviewed study demonstrates that LSD induces faster cortical rhythms and higher fractal dimension in neural activity. These findings clarify the neurobiological basis of LSD’s effects and may influence future clinical research and policy.
Oct 07, 2026
Public HealthA new systematic review finds ice or cold water immersion most effective for drug-induced hyperthermia, but highlights limited targeted data and practical challenges in emergency settings. Evidence gaps persist for psychedelics and novel psychoactives.
Oct 07, 2026
Public HealthItaly’s systematic review of amphetamine-type stimulants (ATS) and synthetic cathinones (SC) uses seizure, wastewater, and toxicological data to reveal regional trends and inform public health and legal strategies for emerging substances.
Oct 07, 2026
NeuroscienceA 2026 mouse study shows tianeptine and opioid peptides enhance hippocampal AMPA receptor function via opioid receptor pathways, highlighting mechanistic links between antidepressants and opioids with implications for rapid-acting treatments and abuse risk.
Oct 07, 2026
Clinical TrialsImplanted vagus nerve stimulation (VNS) demonstrates robust, durable antidepressant effects in severe treatment-resistant depression, as shown in the RECOVER trial. Mechanistic insights and policy implications are explored for future research and clinical use.
Oct 07, 2026
PolicyClearmind's submission of recommendations to the FDA marks another step in industry-regulator engagement on psychedelic therapies. While not a policy shift, this move may influence future FDA guidance and the evolving regulatory landscape.
Oct 07, 2026
NeuroscienceA 2026 MEG study demonstrates that LSD increases neural complexity and shifts brain rhythms, providing new mechanistic insights and potential biomarkers for psychedelic research, with implications for future clinical trials.
Oct 07, 2026
Clinical TrialsA new systematic review synthesizes evidence on ketamine's efficacy and safety for PTSD in military and veteran populations, revealing preliminary benefits but underscoring gaps in trial scale, design, and long-term safety reporting.
Oct 07, 2026
PolicyA landmark 2026 study quantitatively profiles tryptamines, phenethylamines, and β-carbolines across 53 Australian Acacia species, revealing high psychoactive alkaloid concentrations in flowers and leaves. These findings challenge assumptions about tissue-specific compound distribution, with direct implications for conservation, law enforcement, and future psychedelic research.
Oct 07, 2026
Clinical TrialsThe U.S. Department of Veterans Affairs has begun a clinical trial investigating psilocybin-assisted therapy for veterans with depression, reflecting increased federal engagement in psychedelic research and its potential policy impact.
Oct 07, 2026
Public HealthA new analysis calls for U.S. psychedelic policy to support non-clinical uses, highlighting historical precedent and public health potential. The review critiques current healthcare models and prohibitionist policies.
Oct 07, 2026
PolicyClearmind's submission of psychedelic therapy recommendations to the FDA marks a notable industry step in shaping U.S. regulatory pathways. This briefing analyzes the process, potential impacts, and key uncertainties for stakeholders.
Oct 07, 2026
NeuroscienceA new animal study shows (2R,6R)-hydroxynorketamine reverses PTSD-like behaviors in female rats exposed to blast injury, mirroring prior male data and supporting further research into its use for trauma-related disorders.
Oct 07, 2026
Clinical TrialsA new systematic review published in October 2026 concludes that evidence is currently insufficient to support ketamine as a treatment for borderline personality disorder (BPD), depression, or suicidality in BPD patients, citing methodological limitations and a need for further research.
Oct 07, 2026
Clinical TrialsUSC's new clinical trial investigates the combined impact of psilocybin and mindfulness meditation on depression, potentially shaping future therapeutic protocols and regulatory perspectives for psychedelic-assisted treatments.
Oct 07, 2026
PolicyClearmind’s submission of psychedelic therapy recommendations to the FDA highlights the growing role of private industry in shaping U.S. federal policy. This engagement may influence future regulatory guidance, but legal access remains unchanged for now.
Oct 07, 2026
PolicyClearmind has submitted recommendations to the FDA regarding psychedelic therapy, reflecting industry attempts to influence future regulatory guidance. This move signals active engagement but does not guarantee policy change or new access pathways.
Oct 07, 2026
Clinical TrialsUSC's psilocybin-mindfulness trial for depression marks a significant step in academic psychedelic research, integrating established mental health practices with novel pharmacological interventions in a controlled university setting.
Oct 07, 2026
Clinical TrialsA new systematic review details how modern antidepressants—especially glutamatergic agents such as esketamine—bridge traditional and psychedelic pharmacology, influencing clinical research, safety benchmarks, and personalized medicine.
Oct 06, 2026
Clinical TrialsA new framework published in October 2026 offers clinicians a structured method for integrating ego dissolution experiences in psychedelic therapy, blending neurobiological and psychological insights to inform safer, more effective practice.
Oct 06, 2026
Public HealthA new study reveals US counselors lack formal training and standards for psychedelic-assisted therapy, highlighting risks to clients and practitioners. The findings call for targeted education, interdisciplinary collaboration, and regulatory action as PAT becomes more common.
Oct 06, 2026
NeuroscienceA 2026 preclinical study reports that intranasal proenkephalin-expressing stem cells reduce morphine dependence and restore neurotrophic factors in rats. This novel approach could inform future addiction treatments, but human translation remains distant.
Oct 06, 2026
Clinical TrialsA new clinical trial shows ketamine produces significant short-term reductions in insomnia and anxiety among patients with treatment-resistant depression (TRD), with insomnia improvements occurring independently of mood or anxiety changes. These findings may shape future clinical protocols and research.
Oct 06, 2026
Clinical TrialsA 2026 systematic review finds group psychedelic-assisted therapy may improve mental health outcomes and offer cost benefits, but current evidence is limited by methodological weaknesses and a lack of controlled trials.
Oct 06, 2026
MarketOptimi Health’s shares fell 5.6% even as its Phase 2 psilocybin trial advanced, highlighting a disconnect between research progress and market sentiment. This dynamic may influence funding and the pace of psychedelic drug development.
Oct 06, 2026
Clinical TrialsClinicians face nuanced choices between ketamine and esketamine for treatment-resistant depression (TRD), with implications for efficacy, safety, access, and reimbursement. Ongoing research and real-world use will inform future guidelines.
Oct 06, 2026
PolicyThe DEA’s new registration forms for medical marijuana entities clarify federal oversight and may foreshadow regulatory pathways for psychedelics. Stakeholders should examine these changes for compliance signals and future policy direction.
Oct 06, 2026
PolicyThe FDA's new exemption for select class II clinical toxicology devices from 510(k) review streamlines regulatory pathways, enabling faster development and deployment of assays relevant to psychedelic research, clinical trials, and safety monitoring.
Oct 06, 2026
PolicyThe FDA’s public request for information on ibogaine clinical trial design signals a major advance for federally supported research into ibogaine as a potential therapy for opioid use disorder and PTSD, with broad implications for trial safety, oversight, and future regulation.
Oct 06, 2026
Clinical TrialsA recent review identifies psychedelic-assisted therapy as a promising, but not yet guideline-recommended, option for anxiety and depression in cancer patients. The analysis highlights research gaps and the need for rigorous trials before integration into standard oncological care.
Oct 05, 2026
NeuroscienceA new study finds that extended amygdala regions are more responsive to threat probability than uncertainty, challenging established models of anxiety neurobiology and impacting future clinical trial and biomarker development.
Oct 05, 2026
Clinical TrialsA new Johns Hopkins trial shows repeated psilocybin dosing is safe and may reduce OCD symptoms in patients unresponsive to standard therapies, supporting further clinical investigation of psychedelics for OCD.
Oct 05, 2026
Clinical TrialsGlobal research on ketamine in perioperative neurocognitive disorders has accelerated since 2020, with China and the US leading. However, increased publication volume does not equate to proven clinical efficacy, underscoring the need for standardized definitions and robust multicenter trials.
Oct 05, 2026
Clinical TrialsA preprint published on October 5, 2026, presents therapists’ qualitative perspectives from a randomized controlled trial of psilocybin-assisted therapy for major depressive disorder. This analysis explores the findings, implications for clinical practice, and the need for further validation.
Oct 05, 2026
Clinical TrialsA 2024 Bangladesh case series found only half of patients with treatment-resistant depression and suicidality responded to IV ketamine, emphasizing patient heterogeneity and the need for tailored approaches in real-world psychiatric care.
Oct 05, 2026
Clinical TrialsA new analysis urges restraint in the widespread adoption of psychedelic-assisted therapies, citing small sample sizes, short follow-up, and methodological gaps in current clinical trials. Stronger evidence is needed for safety, durability, and real-world effectiveness.
Oct 05, 2026
Clinical TrialsRecent analyses indicate that psilocybin's impact on social cognition in Alcohol Use Disorder (AUD) may be overlooked by standard clinical trial endpoints, potentially underestimating its therapeutic value and influencing regulatory decisions.
Oct 05, 2026
PolicyElevate Holistics’ launch of a telehealth platform for at-home, low-dose ketamine therapy expands access but highlights unresolved US regulatory, safety, and clinical oversight issues as psychedelic telemedicine grows.
Oct 05, 2026
PolicyThe FDA's call for public input on ibogaine research reflects increased federal attention to psychedelics, with possible effects on clinical trials, legal clarity, and future guidance for researchers and sponsors.
Oct 05, 2026
NeuroscienceA 2026 systematic review synthesizes evidence on EEG aperiodic activity across major psychiatric disorders, finding these measures are more useful as within-subject markers of cortical state and treatment response than as diagnostic tools. Implications for psychedelic research include the need for methodological harmonization and physiological validation.
Oct 04, 2026
PolicyThe FDA has announced an official approval pathway for psilocybin, LSD, and other psychedelics, paving the way for prescribable use and reshaping research, legal risk, and industry development in the United States.
Oct 04, 2026
NeuroscienceGrowing scientific attention is turning to psychedelics as possible neurotherapeutic agents for disorders of consciousness, a field with few effective treatments. This analysis reviews mechanisms, research priorities, policy context, and key uncertainties.
Oct 03, 2026
PolicyThe U.S. regulatory gap between FDA-approved esketamine and off-label ketamine use complicates clinical practice, insurance coverage, and research. This analysis explores the mechanisms, legal risks, and policy implications shaping the future of ketamine-based therapies.
Oct 03, 2026
Clinical TrialsA 2026 review highlights SIADH as the pathophysiological link between serotonergic toxicity and hyponatremia, affecting both antidepressant and psychedelic use. This insight prompts updated clinical vigilance, trial design, and risk management.
Oct 03, 2026
Clinical TrialsA recent patent disclosure describes novel 5-HT2A receptor agonists with potential applications in depression, anxiety, substance abuse, and headache disorders. This early-stage development highlights ongoing innovation but requires extensive preclinical and clinical validation.
Oct 02, 2026
NeuroscienceA 2026 preclinical study demonstrates that ibogaine promotes synaptic plasticity and neural repair in mice by inducing metabolic preconditioning, highlighting mitoKv1.3 and sigma-2 receptors as key molecular targets. Translation to clinical applications remains unproven.
Oct 02, 2026
Public HealthThe Cornell case draws attention to ketamine's misuse in sexual assaults, raising urgent legal and public health questions as clinical and non-clinical access expands. Regulatory and policy responses are now under debate.
Oct 02, 2026
NeuroscienceA 2026 study reveals that sex-typical brain connectivity patterns are linked to mood disorders and neurodegeneration risk, underscoring the importance of sex-specific approaches in future clinical trials and biomarker development.
Oct 02, 2026
Clinical TrialsA 2026 JAMA Psychiatry proof-of-concept trial tested IL-6 antagonist tocilizumab for depression with inflammation. While results were not statistically significant, the study signals growing interest in immune-targeted approaches for mood disorders.
Oct 02, 2026
PolicyAccelerating psychedelic drug development in the U.S. is outpacing federal regulatory guidance, causing uncertainty for access, compliance, and research. Contrasting state and federal approaches amplify the challenge, underscoring the need for harmonized approval pathways.
Oct 02, 2026
Clinical TrialsA Phase 2 trial published in October 2026 shows semaglutide significantly reduces heavy drinking in moderate to severe alcohol use disorder, but not cravings—impacting future AUD treatment standards.
Oct 02, 2026
NeuroscienceA 2026 study provides the first high-resolution molecular and anatomical map of the human habenula, revealing cell-type and genetic risk links to depression. These findings underpin future translational research and clinical trial design for psychedelic therapies.
Oct 02, 2026
Clinical TrialsA new secondary analysis reports modest antisuicidal effects of repeated ketamine infusions in treatment-resistant depression, but fails to identify reliable plasma biomarkers. The study highlights both the therapeutic potential and research gaps in ketamine’s rapid-acting effects.
Oct 02, 2026
Clinical TrialsA 2026 PubMed review examines the evidence for psychedelic-assisted psychotherapy, noting increased acceptance, efficacy signals, and the need for more robust studies to inform clinical, regulatory, and funding decisions.
Oct 01, 2026
NeuroscienceRecent preclinical research identifies astrocytic Connexin 43 dysfunction as a driver of Parkinson’s pathology, suggesting new targets for disease-modifying therapies. The findings may inform future translational research, including psychedelic and neuroplasticity-based approaches.
Oct 01, 2026
Clinical TrialsA systematic review published October 2026 synthesizes clinical and preclinical evidence for short-acting tryptamines—N,N-DMT, 5-MeO-DMT, and zalsupindole—highlighting rapid antidepressant effects, safety signals, and the need for more research on mechanisms and hallucinogenic experience.
Oct 01, 2026
NeuroscienceA 2026 preclinical study demonstrates that astrocytic P2X7 receptors mediate stress-induced depressive behaviors in mice, with both genetic manipulation and electroacupuncture alleviating these effects. These findings may inform future research into novel antidepressant targets and adjunctive therapies.
Oct 01, 2026
NeuroscienceA 2026 study reveals that electroconvulsive therapy (ECT) shifts brain network dynamics and neurotransmitter activity in treatment-resistant depression, providing mechanistic insights relevant to psychedelic research and neuromodulation strategies.
Oct 01, 2026
NeuroscienceA 2026 study shows that behavioral activity in rats strongly impacts EEG outcomes, highlighting a critical confound for preclinical psychedelic research and urging stricter standardization of animal neurophysiology protocols.
Oct 01, 2026
NeuroscienceGLPG3970, a selective SIK2/3 inhibitor, demonstrates antidepressant-like effects in chronic stress mouse models by modulating the hippocampal SIK2-CRTC1-CREB-BDNF pathway. The findings offer mechanistic insights relevant to both neuroscience and the development of novel antidepressants.
Oct 01, 2026
EthicsA 2026 analysis highlights ethical and epistemic risks in psychedelic-assisted therapy, urging clinicians, training programs, and credentialing bodies in the US to address vulnerabilities in memory and authority dynamics, especially for trauma survivors.
Oct 01, 2026
Clinical TrialsA recent US psilocybin-assisted psychotherapy trial found participants prefer therapists with personal psychedelic experience, regardless of their own use. This insight complicates hiring, training, and ethical standards in psychedelic research and clinical care.
Oct 01, 2026
PolicyNew Mexico’s Medical Psilocybin Act establishes the first statewide, clinician-led medical psilocybin program in the U.S., setting a precedent for regulated access and influencing future state and federal policy.
Oct 01, 2026
NeuroscienceA 2026 neuroscience study published in PubMed examines how psilocybin affects 'embeddedness,' a self-perception construct. The findings may inform future trial endpoints and therapeutic models, while highlighting new mechanistic questions for psychedelic research.
Oct 01, 2026
NeuroscienceA 2026 review of neurospirituality highlights distributed brain networks underlying spiritual experience and its clinical relevance, but finds evidence remains correlational and clinical guidance is consensus-based, not trial-driven.
Oct 01, 2026
NeuroscienceA 2026 study finds dexmedetomidine may protect against ketamine-induced neurotoxicity in neonatal brains via caspase-1 modulation, raising new questions for pediatric anesthesia guidelines and neurodevelopmental safety.
Oct 01, 2026
Clinical TrialsA 2026 systematic review integrates evidence on ketamine’s psychiatric uses, safety, and policy challenges, highlighting both its rapid antidepressant effects and the risks of off-label and telehealth prescribing.
Oct 01, 2026
PolicyAgarikon provides a validated, source-cited global index of psychedelic clinics, trials, researchers, legislation, and industry, addressing data fragmentation and enabling high-trust policy, clinical, and market research.
Oct 01, 2026
PolicyAgarikon launches a rigorously screened, transparent index aggregating psychedelic medicine clinics, trials, researchers, laws, and industry actors, enabling reliable mapping and risk assessment for global stakeholders.
Oct 01, 2026
PolicyAgarikon launches a first-of-its-kind, auditable global index for psychedelic medicine, unifying clinics, trials, researchers, legal statutes, and industry data. Its transparent methodology and legal-status tagging set a new benchmark for due diligence and policy analysis.
Oct 01, 2026
Public HealthA new PubMed-indexed study (2026) documents concrete health and safety risks from self-medicating with psychedelics, offering data to guide regulatory, clinical, and harm reduction strategies as non-medical use expands.
Oct 01, 2026
PolicySSDP's campaign to influence FDA psychedelic drug regulations marks a new phase of grassroots engagement, potentially impacting future federal policy and access pathways for psychedelic therapies.
Oct 01, 2026
NeuroscienceBig data is reshaping psychiatric and psychedelic research, enabling new insights but also demanding careful attention to methodology, clinical relevance, and conceptual clarity to avoid misinterpretation.
Oct 01, 2026
PolicyThe DEA's October 2026 proposal to require detailed reporting of suspicious controlled substance orders may increase oversight but also complicate research and supply chains for psychedelics. Stakeholders should assess compliance and operational impacts.
Oct 01, 2026
PolicyThe DEA's proposed extension of the reexportation period for controlled substances from 180 to 365 days aims to streamline international supply chains for research and pharmaceutical firms, with implications for global psychedelic research and compliance.
Oct 01, 2026
LegalA 2026 conceptual analysis reveals that 'drug' and 'narcotic drug' have discipline-specific meanings, with legal definitions often diverging from scientific ones. This distinction is critical for research, clinical practice, and policy in psychedelics.
Sep 30, 2026
Clinical TrialsA new preregistered study (NCT04749264) finds that lower baseline depression and anxiety—not higher—correlate with more distress during intensive mindfulness meditation retreats. These findings challenge prevailing risk models for non-ordinary states and may influence future safety assessments for both meditation and psychedelic interventions.
Sep 30, 2026
Public HealthA new scoping review finds that the self-medication hypothesis for ADHD in adults is inconsistently supported across psychoactive substances, with most evidence relying on associations rather than direct symptom change. This nuanced mapping has implications for research, clinical practice, and policy.
Sep 30, 2026
Clinical TrialsA new preprint explores the biological mechanisms behind ketamine’s antidepressant and anti-alcohol effects in alcohol use disorder (AUD) patients. The findings are preliminary, not peer-reviewed, and intended to inform future research, not clinical practice.
Sep 30, 2026
NeuroscienceA recent book argues psychiatry must overhaul its diagnostic system, introducing Neuroanalysis and Clinical Brain Profiling to guide personalized, neuroscience-based treatments—including psychedelic therapies. This shift could reshape research, clinical trials, and regulatory standards.
Sep 30, 2026
Clinical TrialsA recent case report describes worsened depression and anxiety after psilocybin use in a patient with cyclothymia, underscoring the need for rigorous screening and risk management in psychedelic research and clinical practice.
Sep 30, 2026
PolicyThe US Department of Veterans Affairs has initiated a psilocybin study for veterans, reflecting increased federal engagement in psychedelic research. Experts highlight the need for independent research and funding to ensure robust, unbiased evidence and policy development.
Sep 30, 2026
PolicyThe DEA's plan to schedule a postpartum depression breakthrough compound as Schedule I could block research and access, despite FDA recognition of its therapeutic potential, and highlights a growing conflict between drug enforcement and medical innovation in the US.
Sep 30, 2026
Clinical TrialsA new clinical trial is testing the efficacy of psilocybin for depression in lung cancer patients, marking a significant step in psychedelic research for oncology-related mental health. The study's results could shape future clinical guidelines and regulatory decisions.
Sep 30, 2026
Clinical TrialsA new PubMed-indexed study finds that a psychedelic compound can protect against chemotherapy-induced neuropathy, suggesting a promising new direction for managing cancer treatment side effects. Further trials and regulatory review are needed.
Sep 29, 2026
NeuroscienceAutomated home-cage monitoring (HCM) systems are transforming mouse phenotyping in psychiatric research, offering more valid and reproducible data for preclinical studies. This advance may accelerate novel therapeutic discovery, including psychedelics, but raises new challenges for data harmonization and clinical translation.
Sep 29, 2026
Public HealthA new test-retest study demonstrates that self-reported psychedelic use in US population surveys is highly reliable across 17 substances, supporting the validity of epidemiological data that inform policy, public health, and research.
Sep 29, 2026
Public HealthCanada’s adoption of emerging portable drug-checking technologies could transform harm reduction and public health surveillance, but implementation faces analytical, operational, and equity challenges.
Sep 29, 2026
Public HealthA new US cross-sectional study provides the most comprehensive data to date on adverse health outcomes associated with major psychedelics, guiding future clinical trials, policy, and risk assessment.
Sep 29, 2026
Clinical TrialsA new review analyzes phase IIb/III trials of psilocybin for treatment-resistant depression, reporting significant efficacy but also safety concerns like suicidal ideation and HPPD. Germany’s compassionate use program sets a European access precedent.
Sep 29, 2026
Clinical TrialsA Phase 1 trial of oral Ketamir-2, a selective NMDA antagonist, shows favorable safety, tolerability, and pharmacokinetics in healthy adults, with no serious adverse or dissociative effects, supporting progression to Phase 2a neuropathic pain trials.
Sep 29, 2026
Clinical TrialsA pilot RCT (NCT06235411) finds psilocybin reduces egocentric bias in patients with alcohol use disorder, suggesting a novel mechanism for therapeutic effects. Results are preliminary but may inform future clinical research and policy.
Sep 29, 2026
CommunityA new study reveals that while global discourse frames Nepalese 'mad honey' as a psychedelic, local actors emphasize its medicinal and ritual roles, resisting commercialized psychedelic narratives. This highlights the importance of local context for researchers and industry.
Sep 29, 2026
Public HealthA new study presents a reproducible framework for evaluating psychedelic harm reduction at large-scale events, enabling rigorous assessment of peer support interventions and informing future policy, research, and event-health practices.
Sep 29, 2026
Clinical TrialsA major 2026 meta-analysis finds ketamine and ECT equally effective for most severe depression, but ECT remains superior for hospitalized or psychotic patients. Ketamine offers cognitive advantages for ambulatory cases, reshaping guidelines and payer decisions.
Sep 29, 2026
Clinical TrialsA Calgary-based clinical trial is investigating psychedelic-assisted therapy for PTSD in survivors of partner violence, aiming to expand the evidence base for trauma-focused interventions and inform future mental health policy and practice.
Sep 29, 2026
Clinical TrialsFilament Health has shipped its psilocybin drug PEX010 for a Phase 2 clinical trial on PTSD at the University of Calgary, highlighting growing academic-industry collaboration and potential new regulatory pathways for psychedelic therapies in Canada.
Sep 29, 2026
PolicyAfter the FDA’s historic 2026 hearing on psychedelic therapies, a student-led grassroots group has mobilized to shape policy and research. Their engagement signals a new force in advocacy, with implications for future regulation and public health.
Sep 29, 2026
Clinical TrialsA September 2026 PubMed study demonstrates ketamine’s effect on neural and behavioral spatial working memory precision in humans, raising important questions for clinical trial design, psychiatric risk assessment, and regulatory oversight.
Sep 28, 2026
Public HealthA 2026 meta-analysis synthesizes evidence that serotonergic psychedelics may have anti-inflammatory and immunomodulatory effects, potentially expanding their clinical relevance beyond psychiatry. This finding could shape future research, regulation, and funding priorities.
Sep 28, 2026
Public HealthA 2026 review details the clinical challenges of managing acute intoxications from emerging synthetic drugs, emphasizing syndromic recognition, stabilization protocols, and neuropsychiatric outcomes. Integrated emergency, toxicology, and psychiatric care is essential as novel compounds proliferate.
Sep 28, 2026
NeuroscienceA 2026 systematic review and meta-analysis finds consistent anti-inflammatory effects of serotonergic psychedelics in preclinical models, but human evidence is sparse and mixed, underscoring the need for rigorous clinical trials before drawing therapeutic conclusions.
Sep 28, 2026
Clinical TrialsA new review examines rapid-acting and neuromodulatory interventions—including psilocybin and ketamine—for treatment-resistant OCD. While early results are promising, robust evidence and regulatory clarity remain limited.
Sep 28, 2026
NeuroscienceA September 2026 study finds that persistent perceptual abnormalities in psychedelic users are linked to changes in sensory processing and conditioned hallucinations, with implications for clinical trial design, risk assessment, and public health messaging.
Sep 28, 2026
Clinical TrialsA US-based clinical trial is testing psilocybin-assisted therapy for depression in advanced lung cancer patients, expanding research into psychedelic treatments for complex medical populations. The study's outcomes could influence future clinical practice, regulatory policy, and insurance coverage in oncology and palliative care.
Sep 28, 2026
PolicyThe FDA’s September 2026 hearing on psychedelics showcased broad support for advancing research and regulatory clarity, despite persistent concerns. This event may accelerate clinical trials, rescheduling debates, and market development for psychedelic therapies.
Sep 28, 2026
Public HealthA recent meta-aggregation of user experiences reveals the complexity of post-psychedelic difficulties and underscores the importance of pluralistic, harm-reduction-informed counselling practices, especially outside clinical settings.
Sep 27, 2026
Clinical TrialsA PubMed letter reveals that current proxy-based screening for ibogaine therapy in the US Military Health System overlooks medication-induced CYP2D6 inhibition, posing safety and efficacy risks. This gap calls for real-time pharmacogenomic protocols in both clinical trials and policy.
Sep 26, 2026
Clinical TrialsA 2026 pooled analysis of two RCTs applies network analysis to ketamine treatment for treatment-resistant depression (TRD), revealing which symptoms respond most to ketamine and informing future clinical trial design.
Sep 26, 2026
Clinical TrialsA 2026 pooled analysis of two RCTs details ketamine's symptom-level effects in treatment-resistant depression, informing clinical, regulatory, and payer decisions while highlighting targeted approaches and remaining risks.
Sep 26, 2026
Clinical TrialsA randomized clinical trial published in September 2026 found a single dose of psilocybin reduced cocaine use. Filament Health holds exclusive rights to the trial data and intellectual property, shaping future research, access, and commercialization strategies for psychedelic-based addiction therapies.
Sep 26, 2026
Clinical TrialsFilament Health's expanded GMP psilocybin supply deal with the University of Chieti-Pescara supports the TEMPO trial for treatment-resistant depression in Italy, highlighting evolving European clinical research and pharma-academic partnerships.
Sep 25, 2026
LegalThe FDA's 10-year debarment of Jeffrey Thies for felony trafficking in counterfeit goods underscores heightened regulatory scrutiny of drug importation, with significant implications for compliance in psychedelic research and industry supply chains.
Sep 25, 2026
NeuroscienceA 2026 study integrates advanced molecular dynamics and quantum analyses to map the allosteric mechanisms of 5-HT2 receptors, offering actionable insights for the design of safer, more selective psychedelic and non-hallucinogenic drugs.
Sep 25, 2026
PolicyThe FDA's September 2026 public hearing on psychedelics signals increasing regulatory attention, with potential impacts on psychiatric practice, research protocols, and legal risk. This analysis details mechanisms, policy implications, and what to expect next.
Sep 25, 2026
Clinical TrialsItaly has expanded its first psychedelic clinical trial for treatment-resistant depression, reflecting growing regulatory support and setting a precedent for future research and policy in Europe.
Sep 25, 2026
Public HealthA recent case report documents persistent psychological distress in a young adult following recreational LSD use, emphasizing the importance of individualized risk assessment, harm reduction, and careful screening in both clinical and non-clinical settings.
Sep 24, 2026
Clinical TrialsA recent single-blind crossover study reports no significant subacute effect of ketamine on neural reward processing in healthy adults, suggesting timing and participant selection are critical for future ketamine trials targeting mood disorders.
Sep 24, 2026
NeuroscienceA 2026 PubMed study demonstrates that the temporal structure of stimuli meaningfully shapes the psychedelic experience, offering actionable insights for trial design, therapy, and neuroscience research. This finding may shift best practices in intervention timing.
Sep 24, 2026
Clinical TrialsAn international online study published in September 2026 reports recent psychedelic use may impair cognitive performance and mood, while lifetime use does not cause cognitive decline but may impact psychological and social quality of life. The findings highlight the need for careful distinction between acute and long-term effects in policy and research.
Sep 24, 2026
Clinical TrialsA 2026 narrative review synthesizes recent clinical evidence on psilocybin-assisted psychotherapy for major depressive disorder in Brazil, finding rapid and sustained antidepressant effects but underscoring the need for standardized protocols and longer-term studies before clinical adoption.
Sep 24, 2026
Clinical TrialsA new review synthesizes evidence on ketamine for adolescent treatment-resistant depression, confirming rapid symptom relief but emphasizing safety risks and unknown long-term effects. Clinical use remains limited to specialist settings.
Sep 24, 2026
PolicyA 2026 PubMed study provides the first systematic mapping of ayahuasca's botanical and chemical diversity, offering a foundation for standardizing research, informing regulatory decisions, and guiding clinical trial design.
Sep 24, 2026
Clinical TrialsA new study finds that younger adults report stronger mental health benefits from classic psychedelics, with effects waning in older populations. These results highlight age as a key moderator and urge more nuanced research and regulatory approaches.
Sep 24, 2026
PolicyFisher Clinical Services' DEA import application, published September 24, 2026, signals continued infrastructure development for U.S. psychedelic research. This operational step supports trial sponsors and highlights evolving regulatory and supply chain dynamics.
Sep 24, 2026
Clinical TrialsA 2026 NCBI study analyzes intraoperative ketamine's impact on chronic opioid use after lumbar spine surgery, offering insights for perioperative pain management and opioid reduction strategies.
Sep 23, 2026
NeuroscienceA 2026 preclinical study reveals α,α-trehalose, a natural sugar in Psilocybe cubensis, shows significant antidepressant and anxiolytic effects in animals, mediated by 5-HT1A receptors. Implications for drug development and regulatory pathways are discussed.
Sep 23, 2026
Public HealthA new thesis synthesizes evidence on attachment-based interventions for parental substance use, finding improved parent-child bonds but insufficient proof of reduced substance use. Implications for family-focused policy and research are discussed.
Sep 23, 2026
Clinical TrialsOptimi Health has completed GMP-grade psilocybin production for a Health Canada-approved Phase 2 trial in major depressive disorder, advancing Canada's regulated supply chain for clinical research and future TRD commercialization.
Sep 23, 2026
Clinical TrialsThis analysis synthesizes a decade of global evidence on approved medications for substance use disorders (SUD), providing a crucial benchmark for evaluating emerging psychedelic therapies and highlighting gaps in current treatment efficacy.
Sep 23, 2026
Clinical TrialsA recent double-blind, placebo-controlled study demonstrates that psilocybin and music genre each independently modulate emotional responses in healthy adults, underscoring the importance of music selection in psychedelic-assisted interventions.
Sep 23, 2026
Clinical TrialsA new review of studies on peripheral biomarkers for ketamine and esketamine in depression finds no consistent predictors of treatment response, underscoring the need for standardized, prospective, and multimarker research approaches.
Sep 23, 2026
NeuroscienceA new review links synaptic plasticity to cognitive disorders and highlights psychedelics as promising agents for cognitive enhancement, offering a translational roadmap for researchers and clinicians.
Sep 23, 2026
Clinical TrialsPsilocybin-assisted therapy for alcohol use disorder (AUD) is gaining attention for its clinical promise and cost implications, but treatment gaps and regulatory uncertainty remain. This briefing analyzes the current evidence, policy context, and future directions.
Sep 23, 2026
PolicyOregon regulators have abandoned plans to increase licensing fees for psilocybin service providers after industry and community pushback, aiming to support market stability and broader access while highlighting ongoing policy tensions.
Sep 23, 2026
PolicyThe DEA's 2026 proposal to extend procurement quota certification and recordkeeping rules could impact how researchers and manufacturers access and document controlled psychedelics, with potential effects on compliance, research timelines, and administrative burdens.
Sep 23, 2026
MarketNeuroThera’s expanded U.S. patents on LSD and ketamine compounds signal intensifying commercial positioning in psychedelic therapeutics, with potential impacts on research freedom, competition, and future market access.
Sep 23, 2026
MarketOptimi Health has completed a psilocybin production run, expanding pharmaceutical-grade supply for clinical trials and potential therapeutic use in Canada. This development could address research supply chain gaps, but regulatory and patient access barriers persist.
Sep 23, 2026
MarketThe $45,000 estimated cost for MDMA-assisted therapy in New Zealand underscores significant barriers to access and equity, even as the treatment nears potential FDA and global approvals. High pricing may impact payer decisions, patient inclusion, and the broader psychedelic therapy market.
Sep 23, 2026
PolicyThe DEA's proposed bans on several psychedelics contrast sharply with the FDA's efforts to expand legal therapeutic access, creating regulatory uncertainty for researchers, clinicians, and industry stakeholders in the US.
Sep 23, 2026
LegalThe FDA has issued a five-year debarment against Sanjay Kumar for felony conspiracy to traffic counterfeit goods, barring him from drug importation. This action signals heightened agency scrutiny of drug supply chains, with implications for psychedelic research and compliance.
Sep 23, 2026
MarketNeuroThera and Clearmind's expanded US patent portfolio for LSD, ketamine, and ibogaine combinations reflects intensifying competition and evolving IP strategies in the psychedelic sector, with implications for research, access, and market entry.
Sep 23, 2026
PolicyThe US Department of Commerce's 2026 guidance on zero-tariff rates for specialty pharmaceuticals may reduce import costs for psychedelic compounds if they qualify as orphan drugs or urgent health needs, impacting research and market access.
Sep 23, 2026
Clinical TrialsA 2026 systematic review synthesizes evidence on ketamine, esketamine, and scopolamine for treatment-resistant depression, highlighting rapid onset, maintenance effects, and current limitations. Findings inform clinical and policy decisions.
Sep 23, 2026
Clinical TrialsOptimi Health has produced a GMP-compliant psilocybin capsule batch for Australian clinical trials, strengthening local research infrastructure and regulatory acceptance for psychedelic medicine.
Sep 23, 2026
PolicyU.S. authorities have approved ketamine treatment for veterans with PTSD, expanding access to psychedelic-adjacent care. This move may influence insurance, research, and policy, but safety and long-term outcomes remain under review.
Sep 23, 2026
PolicyThe DEA's September 2026 proposal to schedule five tryptamine psychedelics as Schedule I would impose strict controls, curtailing research and commercial activity while raising new questions for policy, science, and harm reduction.
Sep 23, 2026
Clinical TrialsDefinium Therapeutics’ second Phase 3 trial for anxiety shows a 5.1-point difference, indicating possible clinical benefit for a psychedelic-based therapy. The result could impact regulatory pathways and competitive dynamics in late-stage anxiolytic development.
Sep 23, 2026
NeuroscienceA September 2026 preclinical study shows S-propargyl-L-cysteine can reduce ketamine-induced schizophrenia-like behaviors and neuroinflammation in mice, informing future research on safer use of dissociative therapies.
Sep 22, 2026
Public HealthThe UK’s first pediatric ketamine-induced uropathy clinic reveals early sociodemographic insights into youth affected by ketamine misuse. These findings inform public health, clinical guidelines, and future research directions.
Sep 22, 2026
Clinical TrialsA 2026 PubMed study identifies patient factors associated with subanesthetic ketamine use in the postanesthesia care unit (PACU), offering new data to guide perioperative pain and mood management strategies.
Sep 22, 2026
Clinical TrialsA recent scholarly exchange underscores persistent methodological challenges in measuring subjective effects in ketamine and psilocybin trials. Authors call for standardized, multidimensional assessment tools to improve research rigor and inform future regulatory decisions.
Sep 22, 2026
Clinical TrialsA September 2026 letter critiques inconsistencies in ketamine subjective effects research, urging more rigorous and standardized methodologies to improve the reliability of psychedelic-assisted therapy trials.
Sep 22, 2026
Clinical TrialsA 2026 Leiden University study reports elevated bipolar disorder rates among cluster headache patients, with familial aggregation and increased illicit drug use. These findings inform psychiatric screening and patient selection for psychedelic clinical trials.
Sep 22, 2026
NeuroscienceA new review synthesizes current knowledge of PTSD's neural circuitry and treatment efficacy, underscoring unmet needs and informing the potential role of psychedelic-assisted therapies in future PTSD care.
Sep 22, 2026
NeuroscienceA September 2026 preclinical study reports that psilocybin and ethocybin acutely increase aversive memory retention in stressed male mice, without altering key synaptic proteins. The findings highlight complex implications for psychedelic therapy and memory processing.
Sep 22, 2026
NeuroscienceRecent research synthesizes glutamatergic dysregulation in depression, schizophrenia, and addiction, underscoring mechanistic overlaps and translational challenges for psychedelic and glutamate-targeting therapies.
Sep 22, 2026
NeuroscienceA new 2026 study operationalizes self-inquiry from Advaita Vedanta as a reproducible, first-person method for consciousness research, highlighting its overlap with psychedelic phenomenology and potential for empirical and clinical application.
Sep 22, 2026
NeuroscienceA 2026 study demonstrates that DMT and harmine induce distinct EEG changes at peak psychedelic effect, offering new insights for biomarker development and future clinical trial protocols in psychedelic research.
Sep 22, 2026
Clinical TrialsA September 2026 PubMed commentary identifies major methodological concerns in how ketamine’s subjective effects are assessed, urging researchers and regulators to improve measurement standards to ensure valid, comparable clinical trial outcomes.
Sep 22, 2026
PolicyThe FDA's inaugural public hearing on psychedelic therapies marks a turning point for US drug policy, offering insights into evolving regulatory frameworks, research priorities, and the path toward potential clinical adoption.
Sep 22, 2026
PolicyA 2026 systematized review analyzes if VA/DoD guidelines on intravenous ketamine for TRD reflect current science, highlighting evidence gaps and implications for federal health policy and clinical access.
Sep 22, 2026
Clinical TrialsA 2026 review of psilocybin for treatment-resistant depression finds rapid symptom relief in some patients, but variable durability and notable safety concerns. Confirmatory trials and long-term monitoring are needed before clinical use.
Sep 22, 2026
Clinical TrialsUMBRAA’s multidrug masking strategy seeks to overcome the blinding challenge in psilocybin trials, a key barrier to credible results and regulatory approval. This analysis explores the method, its implications, and the risks ahead.
Sep 22, 2026
Clinical TrialsOptimi Health’s hiring of Dr. Michael Blough to lead clinical development signals a targeted push to accelerate psilocybin and MDMA trials. This leadership move highlights the industry's focus on clinical rigor and regulatory readiness in the Canadian psychedelic sector.
Sep 22, 2026
Clinical TrialsThe U.S. Department of Veterans Affairs is expanding psilocybin research, signaling increased federal engagement with psychedelic therapies for veterans. This move raises important questions about access, eligibility, and policy implications for mental health treatment.
Sep 22, 2026
NeuroscienceA 2026 double-blind EEG study finds that DMT/harmine increases complexity and predictability of neural microstates near the psychedelic peak, supporting key theories of psychedelic brain dynamics and informing future clinical trial design.
Sep 22, 2026
Clinical TrialsOptimi Health has appointed a new lead for its psychedelic depression and PTSD clinical trials, reflecting ongoing evolution in commercial psychedelic research. This leadership change may affect trial strategy, partnerships, and future regulatory engagement.
Sep 22, 2026
PolicyThe FDA has finalized a rule replacing 'animal' with 'nonclinical' in regulatory language, signaling acceptance of alternative safety testing methods. This change may accelerate psychedelic research and foster investment in new preclinical technologies.
Sep 22, 2026
PolicyThe FDA’s proposal to replace ‘animal’ with ‘nonclinical’ testing in regulations marks a pivotal shift, encouraging scientifically valid non-animal safety methods. This change could accelerate psychedelic research and novel therapies by lowering preclinical barriers.
Sep 22, 2026
EthicsA recent philosophical paper applies Merleau-Ponty’s phenomenology to psychedelic therapy, arguing that embodied, transformative experiences—not just neurochemical changes—may underlie lasting therapeutic effects. This framework could shape future research, ethics, and clinical models.
Sep 21, 2026
NeuroscienceA September 2026 PubMed study identifies the serotonin 1B receptor as a key target for depression and anxiety therapies, suggesting new directions for both traditional and psychedelic drug development.
Sep 21, 2026
NeuroscienceA major 2026 review synthesizes evidence that timing deficits are central to schizophrenia’s symptoms and neurobiology, implicating dopaminergic, GABAergic, and NMDA receptor dysfunction. This may inform future psychedelic research on cognition and therapeutic targets.
Sep 21, 2026
NeuroscienceA 2026 meta-analysis confirms ketamine’s measurable modulation of GABA and glutamate in depression, strengthening the neurobiological rationale for its antidepressant effects and guiding future biomarker-driven research and policy.
Sep 21, 2026
NeuroscienceNew research on four DMT derivatives reveals their metabolic pathways, high plasma protein binding, and detection markers, offering critical insights for clinical, forensic, and regulatory stakeholders navigating novel psychoactive tryptamines.
Sep 21, 2026
Public HealthA 2026 case report describes mania and rhabdomyolysis in a patient with prolonged daily psilocybin use, highlighting rare but serious risks and underscoring the need for clear dosing guidance and surveillance.
Sep 21, 2026
Clinical TrialsA 2026 pilot study published on PubMed evaluates the implementation of intravenous ketamine protocols for psychiatric care in general hospital units, highlighting feasibility, safety, and early outcome data relevant to policy, payer coverage, and future research.
Sep 21, 2026
Clinical TrialsThe retraction of a widely cited review on ketamine for acute brain injury disrupts clinical and research guidance, highlighting the need for rigorous evidence and careful reliance on secondary literature in psychedelic medicine.
Sep 21, 2026
Clinical TrialsA pioneering longitudinal study reports that ketamine-assisted psychotherapy is feasible, well-tolerated, and associated with reduced depression and suicidality in adolescents and young adults, informing future clinical trials and regulatory debate.
Sep 21, 2026
PolicyAs FDA decisions on psychedelic therapies approach, the US faces pivotal choices on safety, access, and oversight. This analysis examines regulatory mechanisms, policy implications, and risks shaping the imminent landscape.
Sep 21, 2026
NeuroscienceA new meta-analysis reviews how ketamine modulates GABA and glutamate in depression, using MRS data. Findings refine mechanistic understanding but do not directly affect clinical or regulatory pathways. Implications for biomarkers and trial design are discussed.
Sep 21, 2026
NeuroscienceRecent research highlights the serotonin 1B receptor (5-HT1BR) as a key player in mood regulation and a potential target for novel antidepressant and anxiolytic therapies, including psychedelic compounds like psilocybin.
Sep 21, 2026
Public HealthA cross-sectional survey of nearly 1,000 chronic pain patients in Western Canada found 33% are interested in psilocybin education. Interest was linked to depressive symptoms, lower financial wellbeing, and younger age, signaling a need for targeted, evidence-based resources.
Sep 21, 2026
Clinical TrialsA major 2026 review synthesizes clinical trial data showing psilocybin, with psychological support, yields rapid and significant reductions in treatment-resistant depression symptoms, but highlights the need for further research and careful regulation.
Sep 21, 2026
NeuroscienceResearchers have identified a specific brain signal associated with ketamine’s antidepressant effects, offering new avenues for biomarker-driven research and precision psychiatry. This breakthrough could influence clinical trial design, regulatory review, and future antidepressant development.
Sep 21, 2026
Clinical TrialsA U.S. clinical trial will investigate non-hallucinogenic psilocybin for end-of-life care, aiming to separate therapeutic effects from psychedelic experiences. Results could alter clinical practice, regulatory approaches, and future research.
Sep 21, 2026
Clinical TrialsFilament Health has shipped GMP psilocybin (PEX010) for a pivotal Phase 3 trial targeting psychological distress in palliative care, advancing the evidence base and regulatory prospects for psychedelic-assisted therapy in the U.S.
Sep 21, 2026
PolicyThe FDA’s CMC Development and Readiness Pilot Program, now in its fifth year, provides expedited regulatory support for investigational drugs—including psychedelics—by enhancing communication and risk-based review, potentially accelerating clinical development.
Sep 21, 2026
PolicyThe DEA's decision to classify diphenidine as a Schedule I controlled substance enacts the strictest federal restrictions, limiting research and aligning US law with international obligations. This move reflects federal caution on novel dissociatives and will reshape research access.
Sep 21, 2026
NeuroscienceA new review highlights how regulated cell death pathways contribute to depression’s neurobiology, suggesting novel targets for antidepressant development. These findings may influence future psychedelic research and clinical trial strategies.
Sep 20, 2026
Public HealthThe 2026 WHO-ISoP pharmacovigilance curriculum update expands global drug safety training, raising expectations for monitoring, risk communication, and real-world evidence—key for psychedelic medicine stakeholders.
Sep 20, 2026
Clinical TrialsA 2026 observational pilot study found that intravenous ketamine-lidocaine infusions reduced pain for up to four weeks in refractory neuropathic pain patients, with mild side effects and inconclusive biomarker changes. Controlled trials are needed.
Sep 20, 2026
Clinical TrialsA recent study finds that dissociative effects from esketamine treatment may predict better outcomes for patients with treatment-resistant depression, prompting a re-evaluation of risk-benefit assessments and clinical protocols.
Sep 20, 2026
Clinical TrialsA new PubMed review (2026) details the dual-edged relationship between psychedelics and suicidality, emphasizing both therapeutic potential and serious risks. The findings call for enhanced screening, ethical trial design, and stricter safety protocols.
Sep 19, 2026
Clinical TrialsA September 2026 preclinical study reports chrysin reduces ketamine-induced neurotoxicity and related behavioral changes in animal models, highlighting a possible path to safer ketamine use. The findings prompt further translational and clinical research.
Sep 19, 2026
NeuroscienceA new preclinical study finds that a single ayahuasca dose mitigates behavioral and neurochemical impacts of early-life stress in rats. The results highlight potential research avenues but underscore the need for rigorous human safety and efficacy trials.
Sep 19, 2026
PolicyA national analysis of chemical restraint in U.S. custody (2022–2025) details frequency, agents used, and patient outcomes, highlighting policy gaps and clinical risks surrounding ketamine and similar substances.
Sep 19, 2026
Clinical TrialsA major 2026 review details how classic psychedelics can both reduce and exacerbate suicidality, urging robust screening and support protocols in clinical and research settings to ensure patient safety and ethical practice.
Sep 19, 2026
NeuroscienceA new preclinical study demonstrates that a single ayahuasca dose mitigates depression-like behaviors and neurochemical deficits in rats exposed to early-life stress, supporting further translational research but not yet altering clinical or legal practice.
Sep 19, 2026
Public HealthA public hospital in Argentina has reported the country's first case of intravenous ketamine for treatment-resistant depression, marking a significant step in international adoption and public health integration of psychedelic-assisted therapies.
Sep 19, 2026
PolicyA new PubMed study highlights employment risks, including drug testing and discrimination, for participants in psychedelic research. The findings urge policy reforms and ethical safeguards to protect research subjects.
Sep 18, 2026
Clinical TrialsA September 2026 PubMed study documents employment risks—such as workplace drug testing and job loss—faced by participants in psychedelic clinical trials for chronic pain. This analysis explores implications for trial design, informed consent, and policy.
Sep 18, 2026
Public HealthA new systematic review details the multi-organ toxicity and neuropsychiatric risks associated with chronic recreational ketamine misuse, emphasizing the lack of effective treatments for dependence and the need for multidisciplinary care.
Sep 18, 2026
PolicyA 2026 PubMed review synthesizes psilocybin clinical trial data, providing robust evidence for therapeutic potential and analyzing the implications for U.S. rescheduling and future research.
Sep 18, 2026
NeuroscienceA recent review synthesizes preclinical evidence that ferroptosis, an iron-dependent cell death pathway, may contribute to major depressive disorder (MDD) via neuroinflammation and oxidative stress. While offering novel mechanistic insights, clinical translation remains unproven.
Sep 18, 2026
PolicyThe FDA's September 2026 public hearing on psychedelic therapies highlighted behavioral health groups' concerns about workforce readiness and equitable access, signaling a shift toward infrastructure and policy planning as regulatory decisions loom.
Sep 18, 2026
Clinical TrialsA new review highlights esketamine’s potential as a neuroprotective agent in surgery, detailing mechanisms, clinical evidence, and research gaps. This could shape future perioperative trial designs, but access and regulatory status remain unchanged.
Sep 18, 2026
NeuroscienceA novel human myelin MPS allows individualized modeling of MS pathology and treatment response. While not directly linked to psychedelics, this technology could accelerate translational research and preclinical screening for CNS disorders, including future psychedelic-based interventions.
Sep 18, 2026
Clinical TrialsA new n-of-1 protocol helps differentiate nocebo effects—adverse outcomes from negative expectations—from true drug effects in clinical trials, offering a potential tool for more accurate safety and efficacy assessments in psychedelic research.
Sep 18, 2026
NeuroscienceA 2026 mouse study demonstrates that specific dorsal dentate gyrus neuronal ensembles, or 'fear engrams,' drive both cognitive and affective dysfunction after intense fear. The findings suggest new mechanistic targets for stress-related disorders, with implications for psychedelic and neuromodulation research.
Sep 18, 2026
Clinical TrialsThe newly validated short-form persisting effects questionnaire (PEQ-SF) streamlines assessment of psychedelic experiences, improving data quality and reducing participant burden in clinical and observational research.
Sep 18, 2026
NeuroscienceA September 2026 study demonstrates that LSD triggers adaptive, hormetic stress gene programs in the mouse prefrontal cortex, suggesting enduring effects may involve broader homeostatic processes beyond neuronal plasticity.
Sep 18, 2026
Clinical TrialsA 2026 letter in the Journal of Psychopharmacology calls for nuanced definitions in DMT-assisted therapy trials, highlighting the need to separate drug, psychological, and contextual effects when assessing efficacy and safety.
Sep 18, 2026
Clinical TrialsA 2026 letter in the Journal of Psychopharmacology argues DMT-assisted therapy for substance misuse must be evaluated as a complex intervention, not just a pharmacological exposure—shaping future research protocols and systematic review standards.
Sep 18, 2026
EthicsA new analysis spotlights employment-related risks for participants in psychedelic clinical trials, revealing gaps in legal protections and ethical consent. The commentary urges clearer policies to safeguard volunteers from workplace drug testing and discrimination.
Sep 18, 2026
Public HealthA new peer-reviewed study reveals hallucinogens are now the most commonly used illicit drugs among both urban and rural Americans, outpacing other substances and prompting calls for tailored harm reduction and research policies.
Sep 18, 2026
Clinical TrialsA 2026 study reveals employment-related risks for participants in U.S. psychedelic clinical trials for chronic pain, including workplace drug testing and disclosure dilemmas. These findings have important implications for trial protocols, informed consent, and future policy.
Sep 18, 2026
Clinical TrialsPreliminary results from Definium's LSD trial for anxiety highlight both therapeutic potential and unpredictable patient responses. Simultaneously, Compass Pathways' funding of psilocybin therapist training signals industry commitment to workforce development. These moves shape the future of psychedelic care.
Sep 18, 2026
PolicyA proposed overhaul of the Federal Acquisition Regulation could streamline federal research contracting, affecting how psychedelic science is funded and administered. Researchers and industry should prepare for possible shifts in eligibility and compliance requirements.
Sep 18, 2026
NeuroscienceA September 2026 study finds psilocybin restores social behavior in SAPAP3 knockout mice by engaging prefrontal-hippocampal circuits, offering mechanistic insight for future neuropsychiatric research and trial design.
Sep 17, 2026
Clinical TrialsA 2026 PubMed paper proposes a standardized framework for defining DMT-assisted therapy interventions, highlighting the need for methodological rigor before efficacy trials. This step is crucial for regulatory acceptance and future research design.
Sep 17, 2026
Clinical TrialsA 2026 PubMed study finds ketamine may increase psychosis risk in high-risk individuals, raising questions for trial design, clinical protocols, and access policy as ketamine use expands.
Sep 17, 2026
NeuroscienceA new systematic review synthesizes evidence that (es)ketamine and standard antidepressants yield different effects on default mode network (DMN) connectivity in major depressive disorder, highlighting neurobiological markers and research gaps.
Sep 17, 2026
NeuroscienceA new PubMed study details structure-based design of psychedelic analogs selective for serotonin receptor subtypes, offering potential for safer, more effective compounds and influencing research, policy, and industry strategies.
Sep 17, 2026
Clinical TrialsA new narrative review synthesizes two decades of clinical and biochemical evidence on pharmaceutical management of substance use disorders, emphasizing the need for more robust trials on hallucinogens and precision dosing strategies.
Sep 17, 2026
NeuroscienceA new systematic review identifies the insular and temporal lobes as key regions for ecstatic phenomena in focal epilepsy, offering insights for altered states research and highlighting methodological gaps.
Sep 17, 2026
NeuroscienceA new study demonstrates psilocybin restores social novelty investigation in a genetic mouse model of OCD, with effects linked to infralimbic prefrontal cortex activation. This finding supports further research into psilocybin’s potential for social dysfunction in OCD.
Sep 17, 2026
NeuroscienceA September 2026 study details the structure-based design of psychedelic analogs that selectively target 5-HT2A receptors, avoiding 5-HT2B activation and associated cardiac risks. This approach could accelerate the development of safer psychedelic therapies for neuropsychiatric disorders.
Sep 17, 2026
NeuroscienceA 2026 cryo-EM study details the structural basis for designing psychedelics that activate 5-HT2AR without triggering 5-HT2BR, offering a roadmap to safer compounds and reduced cardiac risk in clinical development.
Sep 17, 2026
PolicyLeading experts have urged the FDA to set clear safety and access standards for psychedelic drugs, highlighting regulatory uncertainty as clinical and commercial activity accelerates. The agency’s response will shape research, patient care, and industry direction.
Sep 17, 2026
Clinical TrialsA new 2026 review synthesizes evidence on emerging therapies for treatment-resistant depression, including psychedelic-assisted approaches. It details mechanisms, efficacy, and integration challenges, with a focus on psilocybin and other novel interventions.
Sep 17, 2026
Clinical TrialsHigh ventilation breathwork (HVB) may induce psychedelic-like states without drugs, enabling research on therapeutic mechanisms and broadening access. Experts see clinical promise for internalizing disorders, but risks and efficacy require further controlled trials.
Sep 17, 2026
PolicyThe FDA's September 2026 hearing on psychedelic medicine exposed fundamental disagreements among experts and stakeholders, underscoring complex challenges in setting approval standards, balancing innovation with safety, and guiding the next phase of psychedelic research and policy.
Sep 17, 2026
PolicyThe FDA's first public hearing on psychedelics, attended by MAPS, represents a watershed in U.S. federal policy. This event may reshape clinical research standards, regulatory pathways, and access to psychedelic therapies.
Sep 17, 2026
PolicyThe FDA’s willingness to discuss psychedelic therapy marks a pivotal regulatory shift, yet broader movement concerns about access and equity remain unresolved. This briefing analyzes the implications, risks, and next steps for stakeholders.
Sep 17, 2026
PolicyClearmind Medicine's testimony at the FDA's 2026 hearing on psychedelics highlights growing regulatory attention to patient access and MEAI trial data, signaling potential shifts in U.S. approval pathways for novel compounds.
Sep 17, 2026
Clinical TrialsA new PubMed paper calls for more rigorous masking in psychedelic trials, citing risks of bias in current protocols. This could reshape trial design, regulatory review, and funding standards for psychedelic research.
Sep 16, 2026
Clinical TrialsA 2026 qualitative analysis finds that patient expectations significantly influence both subjective and therapeutic effects of ketamine in treatment-resistant depression, urging integration of psychological context into research and clinical practice.
Sep 16, 2026
Clinical TrialsOptimi Health’s new Phase 3 trial of MDMA-assisted therapy for PTSD in Canada signals a shift toward broader late-stage psychedelic research, with implications for regulatory pathways, competition, and patient access.
Sep 16, 2026
Public HealthA 2026 review of Brazil’s SUS highlights regional inequalities and outdated drug lists in public mental health care, calling for expanded access to newer treatments and policy reforms to close the gap with international standards.
Sep 16, 2026
Clinical TrialsThe first clinical trial of psilocybin-assisted psychotherapy in adults with treatment-resistant depression and cluster B personality disorders shows early safety and feasibility, but outcome variability and small sample size highlight the need for further research.
Sep 16, 2026
Clinical TrialsA 2026 review of clinical trials finds psilocybin and other psychedelics show rapid antidepressant effects in treatment-resistant depression, but underscores unresolved questions about safety, blinding, and long-term efficacy before clinical adoption.
Sep 16, 2026
Clinical TrialsA 2026 qualitative study explores how people with traumatic brain injury (TBI) perceive psychedelic use, reporting subjective improvements in trauma, mood, and cognition. The findings highlight research gaps and the need for rigorous clinical trials.
Sep 16, 2026
Public HealthA retrospective study of an Oregon psilocybin consultation service finds most patients are well-prepared and low risk, with high trauma and prior use rates. These findings inform clinical and policy approaches as regulated psychedelic access expands.
Sep 16, 2026
Clinical TrialsA rigorous clinical trial finds that a single moderate dose of psilocybin significantly improves self-concept and reduces depressive symptoms in major depressive disorder patients, with neuroimaging revealing specific brain changes.
Sep 16, 2026
Clinical TrialsA new clinical trial shows psilocybin reduces depression and enhances self-concept in major depressive disorder, with brain imaging supporting self-related processing changes. The findings inform future therapy protocols and regulatory discussions.
Sep 16, 2026
Clinical TrialsCalls for improved psychedelic clinical trial design highlight persistent issues with blinding, reproducibility, and methodology. These critiques may shape future research standards, regulatory scrutiny, and access pathways.
Sep 16, 2026
Clinical TrialsThe FDA is nearing approval of a psychedelic therapy for treatment-resistant depression (TRD), signaling a potential paradigm shift in psychiatric care, investment, and policy. This analysis examines the clinical evidence, regulatory context, and the complex implications for patients, providers, and the emerging psychedelic industry.
Sep 16, 2026
PolicyThe FDA’s renewed focus on psychedelics in 2026 may reshape regulatory pathways, accelerate research, and impact patient access, but also introduces new legal, clinical, and investment risks for stakeholders.
Sep 16, 2026
PolicyThe FDA’s September 2026 hearing on psychedelics signals increased regulatory engagement and could shape future approval pathways, clinical trial requirements, and post-approval controls for psychedelic therapies in the U.S.
Sep 16, 2026
PolicyThe FDA's September 2026 public hearing on psychedelics marks a pivotal moment in U.S. drug policy, with political momentum raising prospects for regulatory change. This briefing analyzes the mechanisms, implications, and risks for stakeholders.
Sep 16, 2026
PolicyA patient death and provider misconduct have sharpened FDA scrutiny of psychedelic-assisted care, prompting calls for stricter safety protocols and risk management as regulatory decisions approach.
Sep 16, 2026
PolicyThe FDA’s September 2026 public hearing on psychedelics signals a shift in federal engagement, with potential impacts on regulation, research, and access. This briefing analyzes the event’s mechanisms, implications, and risks for the sector.
Sep 15, 2026
PolicyColorado's decriminalization of certain psychedelics reduces penalties for personal use and possession, but does not legalize sales or regulated access. This policy shift has complex implications for research, law enforcement, and future state and federal reforms.
Sep 15, 2026
NeuroscienceA systematic review and meta-analysis published in September 2026 finds that substance-using populations exhibit significantly higher blood neurofilament light chain (NfL) levels, suggesting increased neurobiological burden. The findings highlight both the promise and limitations of NfL as a biomarker for neuroaxonal injury in the context of psychoactive substance use.
Sep 15, 2026
NeuroscienceA recent MRI case-control study highlights distinct brain structure and connectivity differences in Gambling Disorder, particularly in reward and habit circuits. While not directly tied to psychedelics, these findings inform future research on addiction mechanisms and therapeutic targets.
Sep 15, 2026
PolicyDonald Trump’s public mention of psychedelic therapies in September 2026 signals a shift in mainstream attention, with potential to shape U.S. policy, research priorities, and market sentiment. No immediate legal changes follow, but the move warrants close monitoring.
Sep 15, 2026
Clinical TrialsMusic is a key but underreported factor in psychedelic-assisted psychotherapy trials. Standardizing music's function, rather than its form, may improve research reproducibility and clinical outcomes. This review examines mechanisms, documentation gaps, and policy implications.
Sep 15, 2026
NeuroscienceA recent review synthesizes evidence on how psychedelics may reduce anxiety by 'resetting' hippocampal processing, providing a mechanistic model that could inform clinical trial design and regulatory policy for anxiety-related disorders.
Sep 15, 2026
Public HealthA 2026 analysis proposes that lived experience should inform psychedelic research and policy, offering real-world evidence to improve safety, aftercare, and governance as interventions scale beyond clinical trials.
Sep 15, 2026
Clinical TrialsA recent review finds that while psilocybin and ayahuasca show promise for treatment-resistant depression, trial evidence is limited by strict participant selection, methodological flaws, and unresolved ethical concerns.
Sep 15, 2026
Clinical TrialsCompass Pathways has released new data on the durability of psilocybin therapy for depression, a key milestone for regulatory approval and insurance coverage. This analysis examines the findings, their implications, and the next challenges for clinical adoption.
Sep 15, 2026
Clinical TrialsUSC is initiating a clinical trial to assess the impact of meditation on psychedelic therapy outcomes, aiming to inform best practices and future training standards. The study highlights growing academic focus on optimizing set and setting in psychedelic interventions.
Sep 15, 2026
PolicyThe FDA’s 2026 public hearing on psychedelic therapy standards will shape regulatory pathways, clinical trial design, and commercialization, affecting researchers, clinicians, and industry stakeholders across the U.S.
Sep 15, 2026
PolicyThe FDA's new regulatory framework for psychedelic drug sponsors provides clear guidance for clinical development, aiming to reduce uncertainty and accelerate research, but also introduces new compliance demands and unresolved challenges.
Sep 15, 2026
Clinical TrialsA September 2026 systematic review evaluates the cognitive effects of ketamine and esketamine in treating depression and bipolar disorder, highlighting nuanced impacts, research gaps, and clinical implications.
Sep 14, 2026
PolicyThis briefing compares psychedelic therapy regulation in Australia, Brazil, and the USA, examining policy mechanisms, cultural influences, and persistent challenges around safety, access, and ethics. It provides practical insights for researchers and policymakers.
Sep 14, 2026
NeuroscienceA 2026 mouse study shows prenatal dexamethasone impairs hippocampal neurogenesis and induces depression-like behaviors via epigenetic changes, informing psychiatric risk frameworks and future research on early-life exposures.
Sep 14, 2026
Clinical TrialsGenetic differences in CYP2D6 and CYP2C19 significantly affect psychotropic drug response, with emerging relevance for psychedelic-assisted therapy. Personalized approaches could improve outcomes, but clinical adoption faces operational hurdles.
Sep 14, 2026
NeuroscienceThis analysis examines recent advances in understanding the 5-HT2A receptor's role in psychedelic effects and its therapeutic promise, highlighting mechanistic insights, research gaps, and implications for clinical and policy stakeholders.
Sep 14, 2026
PolicyAt a September 2026 FDA hearing, Jacksonville veterans shared experiences with psychedelic-assisted PTSD therapy, highlighting patient needs and shaping future regulatory and research pathways for these emerging treatments.
Sep 14, 2026
PolicyThe FDA's September 2026 public hearing on psychedelics marks a critical juncture for US regulation, as political and scientific pressures converge on the future of treatments for depression and PTSD. Key outcomes may include new access pathways and changes to scheduling.
Sep 14, 2026
Clinical TrialsOhio State's recent study on psychedelic-assisted therapy for veterans with PTSD marks a notable step in mainstream academic research, with implications for clinical trial design, policy, and access—though key questions on safety and efficacy remain.
Sep 14, 2026
PolicyThe FDA's new plan to expedite patient access to psychedelic therapies could reshape clinical research and industry dynamics, but also raises critical questions about safety, oversight, and equitable distribution.
Sep 14, 2026
NeuroscienceA 2026 pre-registered study finds that the thermodynamic ratio R = E/|O_info| does not universally track consciousness across sleep, anesthesia, and psychedelics, highlighting different informational structures and cautioning against generalizing sleep-based metrics to pharmacological states.
Sep 13, 2026
NeuroscienceA constraint-based model of consciousness, anchored to 5-MeO-DMT's effects, offers testable predictions about neural and subjective dissociation. The theory challenges brain-as-generator views, informing future psychedelic trials and consciousness research.
Sep 13, 2026
NeuroscienceA major new study empirically refutes the universality of a proposed thermodynamic marker for consciousness, revealing that sleep and psychedelic states have fundamentally distinct informational structures, and introduces methodological advances for biomarker research.
Sep 13, 2026
PolicyUS FDA approval of psychedelic therapies will not trigger automatic legal changes in Japan, but will create regulatory and clinical pressures, especially for pharmacists. Japan's strict drug scheduling and counseling mandates shape a distinct response.
Sep 13, 2026
Clinical TrialsRecent phase 3 trials show psilocybin and MDMA can produce strong effects in depression and PTSD, but FDA approval remains out of reach due to ethical and methodological issues. Larger, longer studies are needed.
Sep 13, 2026
Public HealthA 2026 study comparing final-year medical students and ChatGPT found strong agreement on the most harmful drugs but significant divergence on psychedelics, raising questions about AI's role in nuanced drug harm assessment and medical education.
Sep 12, 2026
PolicyFDA’s July 2026 guidance on psychedelic drug trial design clarifies regulatory standards for endpoints, safety, and structure, providing a pivotal reference for sponsors and investigators and signaling a science-driven, risk-managed approach.
Sep 12, 2026
Clinical TrialsA new UC San Diego study uses machine learning and neurophysiological data to predict outcomes for rTMS and esketamine in treatment-resistant depression, highlighting the need for multimodal, individualized frameworks—insights highly relevant to psychedelic therapy development.
Sep 11, 2026
Clinical TrialsA peer-reviewed framework details standardized protocols for at-home racemic ketamine therapy, addressing safety, individualized dosing, and monitoring. This could influence clinical practice, regulatory standards, and the expanding at-home ketamine market.
Sep 11, 2026
NeuroscienceA multinational cohort study (AMP SCZ, NCT05905003) reveals that suicidal ideation and behaviors in youth at risk for psychosis are driven mainly by depression and functional factors, not core psychosis symptoms, with implications for research, clinical trials, and policy.
Sep 11, 2026
Public HealthA major UK cohort study finds lifetime psilocybin or LSD use is associated with stronger pro-environmental attitudes and higher rates of vegetarian diets. While causality remains unproven, these findings highlight new research directions on psychedelics' societal effects.
Sep 11, 2026
NeuroscienceA 2026 computational study questions widely used cardiac interoception measures, introducing a Bayesian model that may reshape endpoints in psychedelic trials and mind-body research. Implications for clinical and mechanistic studies are significant.
Sep 11, 2026
Clinical TrialsA 2026 study demonstrates that analyzing temporal reaction time features in the BDIAT can predict active suicidality with 77% accuracy, outperforming traditional methods. These findings may improve suicide risk assessment in psychedelic clinical trials.
Sep 11, 2026
Clinical TrialsA major 2026 review finds that ketamine and esketamine show inconsistent effects on suicidal ideation in adults with depression, with clearer benefits for depressive symptoms than suicidality. Standardized assessment and follow-up are needed.
Sep 11, 2026
Clinical TrialsA new randomized controlled trial shows intravenous esketamine reduces early postoperative anxiety and depression in colorectal cancer surgery patients, expanding its potential use beyond treatment-resistant depression.
Sep 11, 2026
Clinical TrialsA 2026 pilot trial finds that perceived therapist-patient closeness during MDMA-assisted therapy sessions, not just baseline alliance, predicts improved social anxiety outcomes. This insight may shape future trial design and therapist training.
Sep 11, 2026
Clinical TrialsA 2026 paper introduces the Pharmacology–Experience Asymmetry Framework (PEAF), highlighting the need for equal methodological rigor in studying both drug and experiential variables in psychedelic trials.
Sep 11, 2026
Clinical TrialsA major 2026 review concludes psilocybin's potential for chronic pain relief is supported by preclinical mechanisms but lacks robust human efficacy data, highlighting the urgent need for controlled clinical trials.
Sep 11, 2026
Clinical TrialsA 2026 US pilot trial finds that dynamic feelings of closeness—distinct from general therapeutic alliance—during MDMA-assisted therapy sessions predict improved outcomes for social anxiety disorder, informing future protocols and therapist training.
Sep 11, 2026
Clinical TrialsA 2026 study provides the first direct evidence that ketamine and mood states engage similar SCC brain activity, but with distinct timing and patterns. This insight could shape adaptive DBS protocols for depression, advancing personalized neuromodulation.
Sep 11, 2026
PolicyThe FDA’s new regulatory framework for psychedelic therapies changes how these substances are evaluated and administered in US clinics, affecting trial design, research standards, and patient access. Here’s what it means for researchers, clinicians, and industry leaders.
Sep 11, 2026
Clinical TrialsDefinium’s psilocybin program has received a second FDA Breakthrough Therapy designation, this time for preventing chemotherapy-induced neuropathy. This milestone highlights both new clinical potential for psilocybin and evolving regulatory attitudes toward psychedelics.
Sep 11, 2026
PolicyThe FDA’s decision to hold a public hearing on psychedelic therapies signals a shift toward formal regulatory engagement, with implications for research, clinical practice, and market access. Key risks and opportunities are emerging.
Sep 11, 2026
PolicyDHS proposes removing the 60-day grace period for nonimmigrant visa holders, a change that could disrupt US psychedelic research by accelerating the departure of key international staff after job loss. Organizations must prepare for new compliance and retention challenges.
Sep 11, 2026
Clinical TrialsA September 2026 study identifies clinical correlates among TRD patients who do not respond to ketamine in terms of self-assessed life engagement. Findings may refine patient selection and inform future psychedelic-assisted therapy research.
Sep 10, 2026
NeuroscienceA September 2026 preclinical study shows psilocybin reverses spatial memory deficits in Alzheimer's-model rats, but fails to restore disrupted fronto-hippocampal synchrony. The dissociation between behavioral and neural outcomes raises new questions for translational research.
Sep 10, 2026
PolicyThe FDA's 2026 regulatory framework for psychedelic drugs clarifies clinical research, approval, and oversight standards, reducing legal uncertainty and enabling expanded access to investigational psychedelic therapies in the US.
Sep 10, 2026
Public HealthA 2026 qualitative study of Black Americans' substance use treatment experiences reveals structural barriers, community strengths, and the importance of culturally competent care, offering actionable insights for inclusive psychedelic-assisted therapy protocols and policy.
Sep 10, 2026
Clinical TrialsA large 2026 observational study finds that individuals with more ayahuasca experience in ritual settings report better mental health and spiritual well-being, but causality remains unproven. The findings inform future research and policy on psychedelic use.
Sep 10, 2026
Clinical TrialsActive Deep Dive Therapy (ADDT) introduces a structured, active engagement model for MDMA-assisted psychotherapy, emphasizing free association and unconscious processing. This conceptual advance may inform future clinical trials and reshape therapeutic frameworks for severe and treatment-resistant conditions.
Sep 10, 2026
Public HealthA new FDA adverse event analysis links ibogaine and mitragynine to elevated cardiac arrhythmia risk, matching or exceeding known proarrhythmic drugs. The findings signal likely regulatory scrutiny and stricter cardiac safety protocols as psychedelic therapies advance.
Sep 10, 2026
Clinical TrialsOptimi Health’s upcoming 200-participant psilocybin depression trial in Canada signals increased private investment and research scale, with implications for regulatory approval, clinical practice, and the evolving psychedelic industry.
Sep 10, 2026
PolicyThe FDA’s release of a psychedelic drug framework in the New England Journal of Medicine clarifies regulatory expectations for research and clinical use, shaping the future of psychedelic medicine in the United States.
Sep 10, 2026
Clinical TrialsOptimi Health will conduct a 200-patient Phase 2 trial of natural psilocybin for major depressive disorder, advancing large-scale clinical evidence for plant-derived psychedelics and shaping regulatory and industry pathways.
Sep 10, 2026
PolicyThe FDA’s signal of regulatory flexibility for psychedelic assessment marks a pivotal policy shift, potentially expediting research and drug development while raising new questions about safety, efficacy, and evidence standards.
Sep 10, 2026
Clinical TrialsA Phase 2 clinical trial of psilocybin-assisted therapy for major depressive disorder is set to begin in 2027 in the U.S. This trial aims to generate key data for regulators and payers, with implications for access, safety, and investment.
Sep 10, 2026
MarketCompass Pathways’ partnership with Fluence to develop COMP360 provider training marks a key step toward clinical rollout of psilocybin therapy, addressing workforce gaps and regulatory demands for safe, scalable access.
Sep 10, 2026
PolicyThe FDA's new willingness to consider innovative regulatory approaches for psychedelic drug development may accelerate research and clarify expectations for sponsors, but also raises questions about safety, oversight, and implementation.
Sep 10, 2026
Clinical TrialsOptimi Health will initiate a Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder. This study could yield critical efficacy and safety data, shaping future regulatory and market developments in Canada’s psychedelic sector.
Sep 10, 2026
Clinical TrialsA clinician certificate program for COMP360 psilocybin therapy has been announced, signaling growing infrastructure and standardization as the field awaits FDA approval. The initiative could accelerate safe patient access and shape future clinical practice standards.
Sep 10, 2026
MarketEPIK Biosciences' 34 provisional patent filings for ketamine- and DXM-based combination medicines mark a significant development in psychedelic IP strategy, with potential impacts on clinical research, market exclusivity, and regulatory trends in Asia-Pacific.
Sep 10, 2026
Clinical TrialsA 2026 PubMed perspective argues that minimizing or removing the subjective psychedelic experience could compromise clinical efficacy, challenging current drug development and regulatory approaches. This has major implications for research, policy, and future access.
Sep 09, 2026
EthicsA growing movement to create non-hallucinogenic psychedelics aims for broader medical adoption, but new analysis warns that removing the subjective 'trip' may undermine both efficacy and the unique social value of these therapies.
Sep 09, 2026
Clinical TrialsA review published September 2026 proposes a hierarchical framework for nociplastic pain, emphasizing heterogeneity and biomarker-driven stratification. This model could inform future psychedelic clinical trials targeting chronic pain by enabling more precise patient selection and mechanistic endpoints.
Sep 09, 2026
EthicsA 2026 paper reframes ketamine-induced dissociation as an ethically significant phenomenon, not merely a side effect. It proposes a dual-trajectory model, urging clinicians to tailor safeguards and informed consent to patient context, with implications for trial design and psychiatric care.
Sep 09, 2026
Clinical TrialsA September 2026 preprint proposes a two-threshold model to explain why patients with treatment-resistant depression respond differently to psilocybin-assisted therapy. The model could reshape trial design and patient selection, but awaits validation.
Sep 09, 2026
Clinical TrialsRecent real-world data suggest psilocybin may benefit mood disorders, but absence of peer review and methodological details limits clinical and regulatory impact. The findings highlight the need for rigorous trials and careful policy consideration.
Sep 09, 2026
Clinical TrialsA recent U.S. pilot study reports psilocybin-assisted therapy is safe and potentially beneficial for veterans with PTSD, encouraging further research and informing future clinical and regulatory directions.
Sep 09, 2026
Clinical TrialsCompass Pathways released one-year follow-up data showing durable relief from psilocybin therapy in treatment-resistant depression. This milestone informs FDA deliberations, payer confidence, and future access policy for psychedelic-assisted treatments.
Sep 09, 2026
PolicyThe FDA’s September 2026 public hearing on psychedelic therapeutics, featuring Dr. Angela Fisher’s expert remarks, highlights growing federal engagement and may foreshadow updates to regulatory guidance impacting research, access, and oversight.
Sep 09, 2026
Public HealthEarly news of favorable mental health results from legal psilocybin sessions is generating interest, but without peer-reviewed evidence or clear study design, these findings remain preliminary and warrant careful scrutiny.
Sep 09, 2026
Clinical TrialsA 2026 observational study of 894 patients in a tertiary mood disorders clinic details real-world use of rTMS, ECT, intravenous ketamine, and esketamine, highlighting patterns of treatment resistance and access, and informing future clinical and research directions.
Sep 08, 2026
NeuroscienceA new Transformer-based model maps cell-type-specific gene expression changes after psilocybin exposure, revealing that transcriptional downregulation is more stereotyped than upregulation and that baseline HTR2A expression predicts response separability inversely, reshaping mechanistic understanding.
Sep 08, 2026
NeuroscienceA recent study finds that natural anti-NMDAR1 autoantibodies are associated with reduced depression and PTSD symptoms after traumatic brain injury. This discovery could inform future research on glutamatergic modulation and risk stratification in psychiatric care.
Sep 08, 2026
NeuroscienceA new preclinical study maps how depressive-like behaviors in mice correspond to distinct transcriptional changes in habenular cell types, providing insight into stress resilience, mood disorder mechanisms, and future precision interventions.
Sep 08, 2026
NeuroscienceA 2026 multi-omics study provides direct evidence connecting gut microbiota, inflammatory cytokines, and brain function in major depressive disorder, supporting the gut-brain-immune axis hypothesis and suggesting new intervention targets.
Sep 08, 2026
Clinical TrialsA 2026 peer-reviewed study reports the creation of LSD analogues with improved safety and efficacy. Compounds such as UCD0076 show selective receptor targeting and reduced hallucinogenic and cardiotoxic profiles, informing future clinical development.
Sep 08, 2026
Clinical TrialsA new randomized trial shows that mystical-type experiences during psilocybin treatment predict OCD symptom improvement, while challenging experiences do not. This finding could reshape clinical trial design and regulatory endpoints for psychedelic-assisted therapy.
Sep 08, 2026
NeuroscienceA 2026 preclinical study finds SGE-301 reverses high-frequency rTMS-induced LTP-like plasticity in rats, highlighting NMDA receptor modulation as a tool for probing and potentially controlling neuroplasticity relevant to psychiatric disorders.
Sep 08, 2026
NeuroscienceA September 2026 preclinical study finds psilocybin reduces neuroinflammation and tau pathology in rats with repetitive mild head injury, supporting further investigation into its therapeutic potential for traumatic brain injury.
Sep 08, 2026
NeuroscienceA new review synthesizes preclinical evidence on psychedelics as 'psychoplastogens' for CNS repair, detailing molecular mechanisms and translational challenges, and emphasizing the absence of definitive human trial results.
Sep 08, 2026
Clinical TrialsA new meta-analysis of randomized trials shows MDMA-assisted therapy significantly reduces PTSD and related symptoms. However, small sample sizes, blinding issues, and sponsor concentration temper the findings and raise questions for future research and policy.
Sep 08, 2026
Clinical TrialsRecent clinical evidence indicates regular ketamine infusions could help those with treatment-resistant bipolar depression. This analysis explores the trial context, regulatory landscape, clinical risks, and implications for future research and policy.
Sep 08, 2026
PolicyFisher Clinical Services has applied to the DEA for authorization to import controlled substances, a procedural step with implications for U.S. psychedelic research supply chains and regulatory compliance.
Sep 08, 2026
PolicyMedicare's 2026 NTAP town hall shapes the pathway for novel therapies, including psychedelic-assisted treatments, to gain hospital reimbursement. Understanding this process is essential for stakeholders seeking mainstream adoption.
Sep 08, 2026
Clinical TrialsA Melbourne clinical trial is testing psilocybin with physiotherapy, marking a novel expansion of psychedelic research into physical recovery. The study could reshape protocols and access in rehabilitation medicine if efficacy and safety are demonstrated.
Sep 08, 2026
PolicyUkraine is evaluating US and EU drug policy models to reform its approach to addiction and trafficking, signaling possible regulatory changes and expanded treatment access, though immediate impact on psychedelic research is limited.
Sep 07, 2026
Clinical TrialsA comprehensive review of 1965–1977 US and Canadian psychedelic therapy trials reveals most studies found no lasting patient benefits, challenging the narrative of flawed early research and raising questions for modern trial design.
Sep 07, 2026
EthicsA September 2026 qualitative study reveals unresolved ethical and regulatory challenges around post-trial responsibilities for participants in neurosurgical device research, highlighting the urgent need for clear, actionable policy and institutional guidance.
Sep 07, 2026
Clinical TrialsThe phase 2a trial of TS-161, an mGlu2/3 antagonist with mechanistic similarities to ketamine, was halted early due to low recruitment and lack of clinical efficacy in treatment-resistant depression, highlighting ongoing challenges in developing rapid-acting antidepressants targeting glutamatergic pathways.
Sep 07, 2026
Public HealthA 2026 study comparing Oregon’s supervised psilocybin clients to national users finds Oregon’s model serves older, higher-income, wellness-focused adults, unlike the more diverse and clinically burdened national psilocybin-using population. This demographic mismatch complicates policy and research extrapolation.
Sep 07, 2026
Clinical TrialsA longitudinal biomarker preprint links metabolic burden to esketamine response in treatment-resistant depression, offering early clues for personalized therapy. Findings are preliminary and require validation.
Sep 07, 2026
Clinical TrialsThe Bio-K/NNDC multicenter trial found that intravenous ketamine induces wide-ranging metabolomic changes in adults with treatment-resistant depression, offering mechanistic insights but no validated biomarkers for predicting antidepressant response.
Sep 06, 2026
Clinical TrialsThe Bio-K/NNDC multicenter trial mapped metabolomic changes after IV ketamine in adults with treatment-resistant depression, showing broad metabolic effects and partial remission, but no clear metabolomic predictors of response.
Sep 06, 2026
Clinical TrialsThe Bio-K/NNDC multicenter trial offers the most detailed metabolomic profile of IV racemic ketamine in treatment-resistant depression to date, revealing broad metabolic changes but no predictive biomarkers for antidepressant response.
Sep 06, 2026
Clinical TrialsA new review synthesizes evidence on psilocybin’s potential as an anxiolytic, detailing neurobiological mechanisms, clinical trial data, and unresolved questions shaping research and regulatory priorities.
Sep 05, 2026
Clinical TrialsPhase 2 clinical trials of satoprodil, a GluN2B-selective NMDA modulator, showed no significant efficacy over placebo in major depressive disorder. These results challenge the glutamatergic hypothesis and may shift research and investment strategies.
Sep 05, 2026
MarketRecent investments by high-profile tech figures in U.S. psychedelics signal a shift toward mainstream acceptance and rapid industry growth, but also introduce potential regulatory and ethical complexities.
Sep 05, 2026
PolicyNew Zealand has authorized a psychiatrist to prescribe MDMA, transitioning the drug from research to clinical use. This development presents new opportunities and challenges for clinicians, regulators, and the emerging psychedelic industry.
Sep 05, 2026
PolicyMDMA is now federally prescribable for severe PTSD in the US, following FDA approval. This policy shift enables regulated psychedelic therapy, prompts new research, and raises questions on safety, access, and payer coverage.
Sep 05, 2026
PolicyNew Zealand's approval of MDMA-assisted therapy for trauma care marks a significant regulatory milestone in the Asia-Pacific region, expanding access, shaping research agendas, and prompting policy debates while raising important questions about safety and oversight.
Sep 04, 2026
PolicyA newly published national survey of Irish stakeholders offers early data on attitudes toward psychedelic-assisted therapy, revealing both enthusiasm and significant barriers. These findings may shape future policy, research, and clinical adoption in Ireland.
Sep 04, 2026
NeuroscienceA new preclinical study shows that defective synapto-nuclear signaling underlies motoneuron vulnerability in ALS and that enhancing cAMP/PKA signaling can restore function in a mouse model, offering insights for future neuroplasticity research.
Sep 04, 2026
Clinical TrialsA 2026 controlled EEG study finds that psilocybin’s long-term positive effects may be predicted by sub-acute brain activity changes, not just acute experiences. This insight could reshape clinical trial endpoints and patient selection in psychedelic research.
Sep 04, 2026
PolicyNew Zealand now permits psychiatrists to prescribe MDMA for severe PTSD, making it a global pioneer in clinical psychedelic policy. This decision is expected to influence research, regulatory, and clinical landscapes internationally.
Sep 04, 2026
PolicyThe FDA’s 2026 approval of MDMA as a PTSD treatment represents a pivotal regulatory and clinical milestone, transforming patient access, insurance coverage, and the trajectory of psychedelic medicine in the United States.
Sep 04, 2026
Clinical TrialsA major 2026 review details the complexity of geriatric mental disorders, notes interest in ketamine, and calls out the lack of older adult inclusion in psychiatric and psychedelic trials—an urgent challenge for research and policy.
Sep 04, 2026
Clinical TrialsA pilot trial of MDMA-assisted couples therapy for U.S. veterans with PTSD showed large reductions in symptoms and improved relationship functioning, with no serious safety events. Findings support further research in dyadic psychedelic-assisted therapies.
Sep 04, 2026
PolicyA landmark federal report advises U.S. states to ready their laws and infrastructure for FDA approval of psychedelic therapies, signaling a shift in national policy and highlighting trial design issues such as the blinding problem.
Sep 04, 2026
PolicyNew Zealand’s 2026 approval of MDMA for PTSD treatment marks a global first in clinical psychedelic policy, expanding patient access and setting a precedent for international regulatory harmonization. Key risks, research gaps, and operational challenges remain.
Sep 04, 2026
Clinical TrialsThe Department of Veterans Affairs has launched a psilocybin-assisted therapy trial in Alabama, expanding access to psychedelic research for veterans in conservative regions and signaling a shift in federal engagement with novel mental health treatments.
Sep 04, 2026
Clinical TrialsMD Anderson Cancer Center will conduct a clinical trial testing psilocybin for the prevention of chemotherapy-induced neurotoxicity. This marks a significant step in mainstreaming psychedelic research for non-psychiatric indications and could reshape regulatory and clinical perspectives.
Sep 04, 2026
PolicyNew Zealand’s regulatory approval of MDMA for severe PTSD marks a pivotal shift in psychedelic therapy policy, with implications for clinical practice, research, and international regulatory trends. This briefing examines the decision’s context, mechanisms, and potential impact.
Sep 04, 2026
Clinical TrialsA September 2026 PubMed study reports psilocybin prevents chemotherapy-induced peripheral neuropathy in preclinical models by preserving mitochondrial trafficking, suggesting new therapeutic possibilities and research priorities.
Sep 03, 2026
Public HealthA 2026 study using forensic lab analysis in emergency departments offers objective data on illicit and novel psychoactive drug exposures, improving clinical protocols and informing early warning systems for public health and harm reduction.
Sep 03, 2026
Clinical TrialsA 2026 PubMed study details how ketamine's effects on breathing and cortical function depend on dose in ambulatory anesthesia. These findings may reshape protocols, risk assessment, and regulatory oversight for ketamine use in clinical and off-label settings.
Sep 03, 2026
NeuroscienceA new ENIGMA PTSD Consortium preprint analyzes amygdala-hippocampus connectivity across sites, advancing understanding of PTSD neural circuits and informing future psychedelic research and biomarker development.
Sep 03, 2026
NeuroscienceA 2026 preclinical study finds that the brain’s response to anxiety shifts from serotonergic to dopaminergic pathways depending on stress intensity, challenging assumptions about uniform treatment response and guiding future clinical trial design.
Sep 03, 2026
Clinical TrialsA recent case report describes successful ketamine use for severe opioid withdrawal triggered by buprenorphine. While not peer-reviewed or generalizable, this finding may spark controlled trials on ketamine’s role in acute withdrawal management.
Sep 03, 2026
Clinical TrialsA 2026 review synthesizes multi-omics approaches—pharmacogenomics, metabolomics, and more—in guiding treatment-resistant depression. While discovery signals are promising, most omics-guided strategies remain investigational and lack clinical utility, shaping future psychedelic research but not current practice.
Sep 03, 2026
Clinical TrialsThis analysis reviews 2026 best-practice guidance for short-term ketamine use in depression, highlighting regulatory distinctions, clinical protocols, and key evidence gaps for oral, subcutaneous, and nasal formulations.
Sep 03, 2026
PolicyOregon’s legal psilocybin program demonstrates early positive outcomes in safety and efficacy, offering real-world insights for policymakers, clinicians, and industry leaders considering regulated psychedelic models.
Sep 03, 2026
Clinical TrialsCYB004, a deuterated DMT analogue, showed longer-lasting psychedelic effects and acceptable safety in a Phase 1 trial, but did not resolve pharmacokinetic variability—raising important questions for next-generation tryptamine development.
Sep 03, 2026
PolicyNew Zealand authorizes two psychiatrists to prescribe MDMA for PTSD, moving beyond research trials to real-world clinical use. This decision sets a precedent for future regulatory, clinical, and insurance frameworks in psychedelic medicine.
Sep 03, 2026
NeuroscienceA new review synthesizes evidence on 11β-HSD enzymes in PTSD, revealing their role in local brain glucocorticoid metabolism. These insights may inform future psychiatric drug development and clinical trial design.
Sep 03, 2026
NeuroscienceA 2026 review details how Drosophila models are unlocking genetic and neural mechanisms behind sleep impairments in stimulant use disorder, offering foundational insights for future pharmacological and translational research.
Sep 03, 2026
NeuroscienceUT MD Anderson's new animal study finds psilocybin may prevent chemotherapy-induced nerve injury, highlighting a possible future role in oncology care. While promising, the research is preclinical, and significant regulatory and translational hurdles remain.
Sep 03, 2026
Evergreen guides, US and state policy orientation, and daily signal on science and regulation — The Psychedelic Journal as one journal voice.
Global psychedelic research, law, and access (pillar guide)
US and state law, scheduling, and policy hub (not legal advice)
Guides — plain-English primers on each psychedelic therapy
Tools — quizzes, provider lookups, legal-status checkers
Policy calendar: comment windows and milestones we track on-page
Data hub: calendars, tools, and structured research datasets
Glossary A–Z across compounds, law, and policy terms
Sources & method: what we ingest, how we score it, and limits
Curated reading paths for onboarding and deeper study
Start here: how to use this journal and where to go next
Get the daily briefing in your inbox
Law, clinical science, and policy signal on psychedelic research — on our publish cadence. Start at the The Psychedelic Journal homepage.
Subscribe freeSuggest a tool, topic, or improvement that would make this site more useful.